US20030095924A1 - Galenical formulations - Google Patents
Galenical formulations Download PDFInfo
- Publication number
- US20030095924A1 US20030095924A1 US10/193,187 US19318702A US2003095924A1 US 20030095924 A1 US20030095924 A1 US 20030095924A1 US 19318702 A US19318702 A US 19318702A US 2003095924 A1 US2003095924 A1 US 2003095924A1
- Authority
- US
- United States
- Prior art keywords
- perfluoroalkyl
- dye
- chain
- groups
- stands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 238000009472 formulation Methods 0.000 title claims abstract description 75
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims abstract description 65
- 239000000126 substance Substances 0.000 claims abstract description 36
- 239000002872 contrast media Substances 0.000 claims abstract description 24
- 229940039231 contrast media Drugs 0.000 claims abstract description 18
- 238000003745 diagnosis Methods 0.000 claims abstract description 14
- 239000000975 dye Substances 0.000 claims description 147
- 239000000243 solution Substances 0.000 claims description 68
- 210000001165 lymph node Anatomy 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 26
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 26
- -1 perfluorooctylsulfonyl Chemical group 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 23
- 239000007983 Tris buffer Substances 0.000 claims description 22
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 14
- 125000005647 linker group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000003827 glycol group Chemical group 0.000 claims description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 125000004964 sulfoalkyl group Chemical group 0.000 claims description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 230000003595 spectral effect Effects 0.000 claims description 5
- 238000003325 tomography Methods 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- CEJANLKHJMMNQB-UHFFFAOYSA-M cryptocyanin Chemical compound [I-].C12=CC=CC=C2N(CC)C=CC1=CC=CC1=CC=[N+](CC)C2=CC=CC=C12 CEJANLKHJMMNQB-UHFFFAOYSA-M 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 4
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229940075420 xanthine Drugs 0.000 claims description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 3
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 claims description 3
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229950000688 phenothiazine Drugs 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- CABMTIJINOIHOD-UHFFFAOYSA-N 2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]quinoline-3-carboxylic acid Chemical compound N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O CABMTIJINOIHOD-UHFFFAOYSA-N 0.000 claims description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N Dipicolinic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- ABLUEXYMLJCLIB-UHFFFAOYSA-N oxane-2,3-dicarboxylic acid Chemical compound OC(=O)C1CCCOC1C(O)=O ABLUEXYMLJCLIB-UHFFFAOYSA-N 0.000 claims description 2
- 229940081066 picolinic acid Drugs 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001022 rhodamine dye Substances 0.000 claims description 2
- 239000001016 thiazine dye Substances 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 2
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 238000012285 ultrasound imaging Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 0 [1*][N+]1=C(B=[2H])[Y]C2=C1C=CC(C)=C2 Chemical compound [1*][N+]1=C(B=[2H])[Y]C2=C1C=CC(C)=C2 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 159000000000 sodium salts Chemical class 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000002073 fluorescence micrograph Methods 0.000 description 14
- 210000002751 lymph Anatomy 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000004040 coloring Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 150000004696 coordination complex Chemical class 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 238000012800 visualization Methods 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- XYIMHJMDJGQKAD-UHFFFAOYSA-N 1,2,3,3-tetramethylindol-1-ium-5-carboxylic acid;iodide Chemical compound [I-].C1=C(C(O)=O)C=C2C(C)(C)C(C)=[N+](C)C2=C1 XYIMHJMDJGQKAD-UHFFFAOYSA-N 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- PGIVNKJNVKROAZ-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-[3-[[2-[ethyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetyl]amino]-2-hydroxypropyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(CC)CC(=O)NCC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 PGIVNKJNVKROAZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- HYXRUZUPCFVWAH-UHFFFAOYSA-N ethyl 6-hydroxyhexanoate Chemical compound CCOC(=O)CCCCCO HYXRUZUPCFVWAH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- UDWRJSSBFBSTOO-LZQZHQDYSA-N n-[(1e,3e)-5-phenyliminopenta-1,3-dienyl]aniline Chemical compound C=1C=CC=CC=1N\C=C\C=C\C=NC1=CC=CC=C1 UDWRJSSBFBSTOO-LZQZHQDYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000005005 sentinel lymph node Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- SZYQSIQJZUHWQL-UHFFFAOYSA-N *.C.C.C.CC.CC.CCC.CCCC.CN.NCCN.NCCN[K].O.O.O.O.[HH].[HH].[HH].[HH] Chemical compound *.C.C.C.CC.CC.CCC.CCCC.CN.NCCN.NCCN[K].O.O.O.O.[HH].[HH].[HH].[HH] SZYQSIQJZUHWQL-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- MEUVAJXZPZEGQD-UHFFFAOYSA-N B.C.N Chemical compound B.C.N MEUVAJXZPZEGQD-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OFODKOORVKOJRZ-UHFFFAOYSA-N CC.CC.CC.CC.CC.CCCCN.N.N.N.N.N.O Chemical compound CC.CC.CC.CC.CC.CCCCN.N.N.N.N.N.O OFODKOORVKOJRZ-UHFFFAOYSA-N 0.000 description 1
- VESBIAZVODMMQN-UHFFFAOYSA-N CCC(C(=O)[Y])N1CCN(CC)CCN(CC)CCN(CC)CC1 Chemical compound CCC(C(=O)[Y])N1CCN(CC)CCN(CC)CCN(CC)CC1 VESBIAZVODMMQN-UHFFFAOYSA-N 0.000 description 1
- AQESELROYNPAJZ-UHFFFAOYSA-N CCC(CN(CC)CC)CN(CC)CCN(CC)CC Chemical compound CCC(CN(CC)CC)CN(CC)CCN(CC)CC AQESELROYNPAJZ-UHFFFAOYSA-N 0.000 description 1
- NIRKFGNXPQKSEI-UHFFFAOYSA-N CCC1CN(CC)CCN(CC)CCN(CC)CCN1CC Chemical compound CCC1CN(CC)CCN(CC)CCN(CC)CCN1CC NIRKFGNXPQKSEI-UHFFFAOYSA-N 0.000 description 1
- LZCNTYUCQUJCLW-UHFFFAOYSA-N CCN(CC)CCN(CCN(CC)CC)C(C)COC Chemical compound CCN(CC)CCN(CCN(CC)CC)C(C)COC LZCNTYUCQUJCLW-UHFFFAOYSA-N 0.000 description 1
- FRKUZWLYQOEFHD-UHFFFAOYSA-N CCN(CC)CCN(CCN(CC)CC)CC(=O)N1CCN(SO(O)CC)CC1 Chemical compound CCN(CC)CCN(CCN(CC)CC)CC(=O)N1CCN(SO(O)CC)CC1 FRKUZWLYQOEFHD-UHFFFAOYSA-N 0.000 description 1
- HVHSWMHTYISUNO-CDIPOPGWSA-O CCNC1=C(C)C=C2C(=C1)OC1=C/C(=[NH+]/CC)C(C)=CC1=C2C1=C(C(=O)O)C=C(C(=O)NCCOCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C=C1 Chemical compound CCNC1=C(C)C=C2C(=C1)OC1=C/C(=[NH+]/CC)C(C)=CC1=C2C1=C(C(=O)O)C=C(C(=O)NCCOCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C=C1 HVHSWMHTYISUNO-CDIPOPGWSA-O 0.000 description 1
- WUAZCQAAGSFXDN-UHFFFAOYSA-N Cc1ccc2S(N)=C(C(C=C3)C3=O)[IH][IH]c2c1 Chemical compound Cc1ccc2S(N)=C(C(C=C3)C3=O)[IH][IH]c2c1 WUAZCQAAGSFXDN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- HYOWDNJXLWHNER-UHFFFAOYSA-O O=C(O)C1=C(C2=C3C=C4CCC[N+]5=C4C(=C3OC3=C4CCCN6CCCC(=C46)C=C32)CCC5)C=CC(C(=O)NCCOCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=C1 Chemical compound O=C(O)C1=C(C2=C3C=C4CCC[N+]5=C4C(=C3OC3=C4CCCN6CCCC(=C46)C=C32)CCC5)C=CC(C(=O)NCCOCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=C1 HYOWDNJXLWHNER-UHFFFAOYSA-O 0.000 description 1
- GFOKITYZHYRCMD-UHFFFAOYSA-N O=C1C=CC2=C(C3=C(C(=O)O)C=C(C(=O)NCCOCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C=C3)C3=CC=C(O)C=C3OC2=C1 Chemical compound O=C1C=CC2=C(C3=C(C(=O)O)C=C(C(=O)NCCOCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C=C3)C3=CC=C(O)C=C3OC2=C1 GFOKITYZHYRCMD-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LPTITAGPBXDDGR-LJIZCISZSA-N [(2r,3r,4s,5r,6r)-3,4,5,6-tetraacetyloxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O LPTITAGPBXDDGR-LJIZCISZSA-N 0.000 description 1
- LPTITAGPBXDDGR-WHWZVRATSA-N [(2r,3r,4s,5s)-3,4,5,6-tetraacetyloxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O LPTITAGPBXDDGR-WHWZVRATSA-N 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 150000002991 phenoxazines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
Definitions
- the invention relates to the field of galenical formulations, which are used in particular as contrast media for the visualization of lymph nodes.
- the invention relates to the subject that is characterized in the claims, namely new galenical formulations that contain perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances.
- lymph node metastases are found in about 50-69% of all patients with malignant tumors (Elke, Lymphographie [Lymphography], in: Frommhold, Stender, Thurn (eds.), Radiological Diagnostik ingraphy undtechnik [Radiological Diagnosis in Clinical Studies and Practice], Volume IV, Thieme Verlag Stuttgart, 7th Ed., 434-496, 1984).
- Lymphographie Lymphography
- the diagnosis of a metastatic attack of lymph nodes is of great importance with respect to the therapy and prognosis of malignant diseases.
- lymphogenous metastasis sites of malignant tumors are detected only inadequately, since in most cases, only the size and the shape of the lymph node can be used as a diagnostic criterion.
- small metastases in non-enlarged lymph nodes are not distinguished from lymph node hyperplasias without a malignant attack (Steinkamp et al., Sonographie und Kernspintomographie: Differentialdiagnostik von regenter Lymphknotenvergröberung und Lymphknotenmetastasen am Hals [Sonography and Nuclear Spin Tomography: Differential Diagnosis of Reactive Lymph Node Enlargement and Lymph Node Metastases on the Neck], Radiol. Diagn. 33: 158, 1992).
- the contrast medium could be adminisitered intravasally or interstitially/intracutaneously (see above Siefert, H. M. et al., Lymphology 13, 150-157, 1980).
- the interstitial/intracutaneous administration has the advantage that the substance is transported directly from the scattering focus (e.g., primary tumor) by the corresponding lymph tract into the potentially related regional lymph node stations.
- a high concentration of the contrast medium in the lymph nodes can be achieved with a low dose.
- Such markers that are to be administered interstitially were mainly used in the nuclear-medicine evaluation (with use of radioactive particles, such as, e.g., 198 Au-colloid).
- Nuclear-medicine methods have only a very inadequate spatial resolution, however, in contrast to nuclear spin tomography with its high spatial resolution in the range of fractions of a millimeter.
- the direct x-ray-lymphography injection of an oily contrast medium suspension in a prepared lymph vessel
- Fluorescence-labeled dextrans are also used experimentally in animal experiments to be able to observe the lymph outflow after their interstitial administration.
- lymph-specific contrast-media with suitable pharmaceutical and pharmacological properties.
- pharmaceutical properties focus is placed first on the highest possible contrast medium concentration and an adequate stability.
- pharmacological properties focus is placed mainly on a quick and complete excretion of the contrast medium to avoid an unnecessary load of the entire organism.
- corresponding preparations must have at their disposal an adequate local and acute compatibility.
- the object of this invention is therefore to make available new galenical formulations that are suitable as contrast media especially for the visualization of lymph nodes in the above-mentioned new diagnostic processes, and that-meet the above-mentioned pharmaceutical and pharmacological requirements.
- the new galenical formulations contain perfluoroalkyl-containing dye molecules, which can be used as contrast media in near-infrared diagnosis.
- the dyes satisfy certain photophysical and chemical requirements. They have high absorption coefficients and high fluorescence quantum yields to produce an effective signal even at the lowest tissue concentrations.
- the absorption maxima overlap a wide spectral range in a freely selectable manner. For detection in lower tissue layers (several centimeters under the surface), the spectral range between 600 and 900 nm is essential, while absorption wavelengths of 400 to 600 nm are sufficient for surface detection.
- the dyes further have a high chemical stability and photostability.
- the essential problem is the limited penetration depth of the light, which lies in the submillimeter range in the VIS but can be in the centimeter range in the NIR.
- detection processes in surface tissue diseases, as well as soft tissues are unproblematic. Since a considerable number of tissue changes (e.g., breast tumors, skin tumors, lymph node changes) are located on the surface, optical diagnostic processes in addition to the conventional methods are offered to perform a tissue differentiation based on different absorption and fluorescence patterns. In this case, the pronounced diffusion of light, which obtains increasing influence with growing tissue thickness, reduces both the resolution and the contrast of an optical image.
- Dyes that are used as so-called optical contrast media and are concentrated in the tissues that are to be detected can result in principle in an increase of the diagnostic value of optical detection processes, in which they increase the absorption of the tissue and provide an additional measurement signal with the dye-specific fluorescence, which can be detected arbitrarily often in front of a low tissue background with high sensitivity.
- Polymethine dyes such as, e.g., cyanine dyes, squarilium dyes, croconium dyes, oxonol dyes, merocyanine dyes, cryptocyanine dyes;
- xanthine dyes such as, e.g., fluorescein and rhodamine and derivatives thereof;
- heteroaromatic, cationic dyes such as, e.g., oxazines, phenoxazines, thiazines, phenothiazines.
- the new perfluoroalkyl-containing dye molecules are compounds of general formula I
- R f represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms
- L stands for a linker
- A stands for a dye molecule.
- Linker L is a direct bond or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COO, —SO 3 groups and/or optionally is interrupted by one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR—, —NRCO—, —SO 2 —, —NH—, —NR groups or a piperazine, whereby R stands for a C 1 to C 10 alkyl radical, which optionally is substituted with one or more OH groups and/or is interrupted by one or more oxygen atoms.
- Dye molecule A is a dye from the class of the polymethine dyes, xanthine dyes or the heteroaromatic cationic dyes.
- Dye molecule A is preferably a cyanine dye, squarilium dye, croconium dye, oxonol dye, merocyanine dye, cryptocyanine dye, fluorescein dye, rhodamine dye, oxazine dye, phenoxazine dye, thiazine dye or phenothiazine dye.
- dye molecule A is a molecule according to general formula II:
- D stands for a fragment that corresponds to general formulas III to VI, whereby the position that is characterized with a star means the linkage with B:
- R 1 and R 2 represent a C 1 -C 4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C 1 - C 50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated, cyclic C 5 -C 6 units or bicyclic C 10 units, and whereby the C 1 -C 50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups,
- R 3 stands for a radical —COOE 1 , —CONE 1 E 2 , —NHCOE 1 , —NHCONHE 1 , —NE 1 E 2 , —OE 1 , —OSO 3 E 1 , —SO 3 E 1 , —SO 2 NHE 1 , —E 1 ,
- E 1 and E 2 independently of one another, represent a hydrogen atom, a C 1 -C 4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C 1 -C 50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated cyclic C 5 -C 6 units or bicyclic C 10 units, and whereby the C 1 -C 50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups, and/or is substituted with 0 to 5 hydroxy groups,
- R 4 stands for a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, or a branched or straight-chain C 1 -C 10 alkyl chain,
- X and Y independently of one another, mean O, S, —CH ⁇ CH— or C(CH 3 ) 2 .
- Especially preferred perfluoroalkyl-containing dye molecules contain a perfluoroalkyl radical R f with 6 to 12 carbon atoms, a linker L, which consists of a C 1 -C 10 alkyl group that contains one or more oxygen atoms and/or one or more —CONH—, —NHCO—, —CONR—, —NRCO groups, in which R stands for a C 1 -C 5 alkyl radical, which can be substituted with one or more OH groups and a cyanine dye as a dye molecule.
- the cyanine dyes indocarbocyanine dyes, indodicarbocyanine dyes and indotricarbocyanine dyes are preferred.
- Especially preferred dye molecules are the following compounds:
- p stands for 1, 2 or 3
- R 1 and R 2 independently of one another, stand for a 4-sulfobutyl, 3-sulfopropyl, 2-sulfoethyl-, 3-methyl-3-sulfopropyl, methyl, ethyl or propyl radical, and
- R 3 stands for hydrogen, for a radical —COOE 1 , —CONE 1 E 2 , —NHCOE 1 , —NHCONHE 1 , —NE 1 E 2 , —OE 1 , —OSO 3 E 1 , —SO 3 E 1 , —SO 2 NHE 1 ,
- E 1 and E 2 independently of one another, stand for a hydrogen atom or for a methyl, ethyl or a C 3 -C 6 alkyl radical, which is interrupted by 0 to 2 oxygen atoms and/or by 0 to 1 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups or stands for a poly(oxyethylene)glycol radical with 2 to 30 —CH 2 CH 2 O units.
- the galenical-formulations according to the invention further contain other perfluoroalkyl-containing compounds, e.g., perfluoroalkyl-containing metal complexes.
- perfluoroalkyl-containing metal complexes and their production were already described in the German Laid-Open Specifications DE 196 03 033, DE 197 29 013 and WO 97/26017.
- These perfluoroalkyl-containing metal complexes are compounds of general formula XIV
- R f represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms
- M is a molecule portion that contains 1-6 metal complexes.
- Molecule M stands for, for example, a group L-M 1 , whereby L stands for a linker, and M 1 stands for a metal complex with an open-chain or cyclic chelator, which contains as central atom an atom of atomic numbers 21-29, 39, 42, 44 or 57-83.
- linker L is a direct bond, a methylene group, an —NHCO group, a group
- R 1 means a hydrogen atom, a methyl group, a —CH 2 —OH group, a —CH 2 —CO 2 H group or a C 2 -C 15 chain, which optionally is interrupted by 1 to 3 oxygen atoms, 1 to 2>CO groups or an optionally substituted aryl group and/or is substituted with 1 to 4 hydroxyl groups, 1 to 2 C 1 -C 4 alkoxy groups, 1 to 2 carboxy groups,
- optionally substituted aryls and/or is interrupted by these groups and/or is optionally substituted with 1 to 3 —OR 1 groups, 1 to 2 oxo groups, 1 to 2 —NH—COR 1 groups, 1 to 2 —CONHR 1 groups, 1 to 2 (—CH 2 ) p —CO 2 H groups, 1 to 2 groups —(CH 2 ) p —(O) q —CH 2 CH 2 —R F ,
- R 1 , R F and p and q have the above-indicated meanings
- T means a C 2 -C 10 chain, which optionally is interrupted by 1 to 2 oxygen atoms or 1 to 2 —NHCO groups.
- metal complex M′′ stands for the following metal complexes:
- R 3 has the meaning of R 1 or —(CH 2 ) m -L-R F , whereby m is 0, 1 or 2, and L and R F have the above-mentioned meaning,
- Z 1 independently of one another, mean a hydrogen atom or a metal ion equivalent of atomic numbers 21-29, 39, 42, 44 or 57-83,
- Y means —OZ 1 , or
- R 3 and Z 1 have the above-mentioned meanings
- R 2 has the above-mentioned meaning of R 1
- Molecule portion M according to formula XIV can further exhibit the following structure:
- q 1 is a number 0, 1, 2 or 3,
- K stands for a complexing agent or metal complex or salts thereof of organic and/or inorganic bases or amino acids or amino acid amides
- X is a direct bond for the perfluoroalkyl group, a phenylene group or a C 1 -C 10 alkyl chain, which optionally contains 1-15 oxygen atoms, 1-5 sulfur atoms, 1-10 carbonyl groups, 1-10 —(NR) groups, 1-2 NRSO 2 groups, 1-10 CONR groups, 1 piperidine group, 1-3 SO 2 groups, 1-2 phenylene groups or optionally is substituted by 1-3 radicals R F , in which R stands for a hydrogen atom, a phenyl, benzyl or a C 1 -C 15 alkyl group, which optionally contains 1-2 NHCO groups, 1-2 CO groups, 1-5 oxygen atoms and optionally is substituted by 1-5 hydroxy, 1-5 methoxy, 1-3 carboxy, 1-3 R F radicals,
- Y 1 is a direct bond or a chain of general formula XXVII or XXVIII:
- R 1a is a hydrogen atom, a phenyl group, a benzyl group or a C 1 -C 7 alkyl group, which optionally is substituted with a carboxy group, a methoxy group or a hydroxy group,
- Z 1 is a direct bond, a polyglycol ether group with up to 5 glycol units or a molecule portion of general formula XXIX
- R 2a is a C 1 -C 7 carboxylic acid, a phenyl group, a benzyl group or a —(CH 2 ) 1-5 —NH—K group,
- ⁇ represents the binding to the nitrogen atom of the skeleton chain
- ⁇ represents the binding to the complexing agent or metal complex K
- variables k and m stand for natural numbers between 0 and 10, and 1 stands for 0 or 1, and whereby
- G is a CO or SO 2 group.
- Molecule portion A according to general formula I further can stand for a group L 1 -M 2 , in which L 1 stands for a linker and M 2 stands for a metal complex.
- linker L 1 is a molecule portion according to general formula XXX
- N represents a nitrogen atom
- A1 means a hydrogen atom, a straight-chain or branched C 1 -C 30 alkyl group, which optionally is interrupted by 1-15 oxygen atoms and/or optionally is substituted with 1-10 hydroxy groups, 1-2 COOH groups, a phenyl group, a benzyl group and/or 1-5 —OR 4 groups, with R 4 in the meaning of a hydrogen atom or a C 1 -C 7 alkyl radical, or B1-R F ,
- B1 means a straight-chain or branched C 1 -C 30 alkylene group that optionally is interrupted by 1-10 oxygen atoms, 1-5 —NH—CO groups, 1-5 —CO—NH groups, by a phenylene group (that is optionally substituted by a COOH group), 1-3 sulfur atoms, 1-2 —N(B2)—SO 0 groups, and/or 1-2 —SO 2 —N(B2) groups with B2 in the meaning of A1, an NHCO group, a CONH group, an N(B2)—SO 2 group, or an —SO 2 — N(B2) group and/or optionally is substituted with radical R F ,
- a represents the binding to metal complex M 2
- b represents the binding to perfluoroalkyl group R F .
- metal complex M 2 stands for a metal complex of general formula XXXI
- R 1 stands for a hydrogen atom or a metal ion equivalent of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,
- R 2 and R 3 stand for a hydrogen atom, a C 1 -C 7 alkyl group, a benzyl group, a phenyl group, —CH 2 OH or —CH 2 —OCH 3 ,
- U stands for radical L, whereby L and U, independently of one another, can be the same or different, however.
- Metal complexes with cyclic chelating agents are preferred compared to those with open-chain chelating agents.
- gadolinium complexes are the gadolinium complex of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see WO 97/26017, Example 33),
- perfluoroalkyl-containing metal complexes instead of the perfluoroalkyl-containing metal complexes, other perfluoroalkyl-containing compounds can also be contained in the galenical formulations according to the invention.
- Such compounds are compounds of general formula XXXII
- R f represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms
- L 2 stands for a linker
- G 1 stands for a hydrophilic group.
- Linker L 2 is a direct bond, an —SO 2 group or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COO ⁇ , —SO 3 groups and/or optionally contains one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR′′—, —NR′′CO—, —SO 2 —, —PO 4 —, —NH—, —NR′′ groups, an aryl ring or a piperazine, whereby R′′ stands for a C 1 to C 20 alkyl radical, which in turn can contain one or more O-atoms and/or can be substituted with —COO ⁇ or SO 3 groups.
- Hydrophilic group G 1 stands for a monosaccharide or disaccharide, one or more adjacent —COO ⁇ or —SO 3 groups, a dicarboxylic acid, an isophthalic acid, a picolinic acid, a benzenesulfonic acid, a tetrahydropyrane dicarboxylic acid, a 2,6-pyridinedicarboxylic acid, a quaternary ammonium ion, an aminopolycarboxylic acid, an aminodipolyethyleneglycolsulfonic acid, an aminopolyethylene glycol group, an SO 2 —(CH 2 ) 2 —OH group, a polyhydroxyalkyl chain with at least two hydroxyl groups or one or more polyethylene glycol chains with at least two glycol units, whereby the polyethylene glycol chains are terminated by an —OH or —OCH 3 group.
- Especially preferred perfluoroalkyl-containing compounds contain a perfluoroalkyl radical R f with 6 to 12 carbon atoms, a linker L 2 , which represents an —SO 2 group or a straight-chain or branched carbon chain with up to 20 carbon atoms, which in turn contains one or more —O—, —CO—, —CONH—, —NHCO—, —CONR′′—, NR′′CO—, —SO 2 groups or a piperazine, in which R′′ has the above-indicated meaning, and a monosaccharide as hydrophilic group G 1 .
- the substance mixtures according to the invention can be present in dissolved form in a solvent.
- the solvent is preferably water.
- the proportion of the perfluoroalkyl-containing dye molecule is between 0.1 and 10 mol % relative to the total amount of perfluoroalkyl-containing substances, preferably between 1 and 10 mol %.
- Preferred are mixtures that consist of perfluoroalkyl-containing dye molecules and other perfluroalkyl-containing compounds, in which-the perfluoroalkyl chains have a length of 6 to 12 carbon atoms.
- mixtures in which both the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds have a perfluoroalkyl chain with 8 carbon atoms.
- the new galenical formulations show surprising advantages in their use as contrast media.
- Galenical formulations that consist of perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances can be produced in a wide variety. These formulations are suitable for fluorescence detection and visually detectable staining of lymph nodes after interstitial or intravenous administration.
- Another advantage consists in the fact that the lymph nodes assume a characteristic coloring. In addition to the NIR diagnosis, this allows an intraoperative fluorescence diagnosis of the lymph node morphology and lymph tract permeability as well as a fluorescence-supported removal of biopsies. In this case, the fluorescence-supported detection of the so-called sentinel lymph node is especially important.
- the sentinel lymph node is the first lymph node that drains the lymphs of a tumor area and thus also the first lymph node that is affected in a metastasis attack of lymph nodes.
- the fluorescence-supported detection of these lymph nodes is carried out very much more simply than, e.g., the detection with the aid of radiopharmaceutical agents, since the detection of x-ray radiation is always more difficult than direct detection of fluorescence radiation.
- the stained lymph nodes are to be made visible, since the lymph nodes also can assume a characteristic coloring in the case of the corresponding dosage of the compounds according to the invention.
- the dye molecules are produced in a way that is similar to methods that are known in the literature and then coupled with perfluoroalkyl derivatives.
- Preferred are dyes from the above-mentioned classes, which contain carboxyl groups or isothiocyanate groups.
- those dyes that contain carboxyl groups which after activation with use of standard reagents are reacted with amino groups that contain perfluoroalkyl derivatives with the formation of an amide group.
- Literature for synthesis of polymethine dyes Bioconjugate Chem. 4, 105-111, 1993; Bioconjugate Chem. 7, 356-62, 1996; Bioconjugate Chem.
- the production of the galenical formulations is carried out in that the perfluoroalkyl-containing dye molecule (component A) and the other perfluoroalkyl-containing substance (component B) are weighed and are dissolved in a suitable solvent.
- An especially suitable solvent is water.
- the proportion of the perfluoroalkyl-containing dye molecule is between 1 and 10 mol % relative to the total amount of perfluoroalkyl-containing substances.
- the concentration of the solution is preferably between 0.1 mmol/L and 20 mmol/L relative to the dye.
- This solution is then added in excess to commonly used galenical additives, such as, e.g., buffer solutions and the Ca-salt of the complexing agent.
- the solutions are stirred vigorously.
- the solutions can be treated at 10 to 100° C. in an ultrasound bath.
- Another alternative consists in that the solutions are treated with microwaves.
- solubilizer such as alcohol (e.g., methanol or ethanol) or another water-miscible solvent
- a solubilizer such as alcohol (e.g., methanol or ethanol) or another water-miscible solvent
- the distillation can take place under vacuum.
- the residue is then dissolved in water, and the solution is filtered. It is also possible to dissolve each component per se separately in a solvent, then to join them and to proceed further as above.
- Such produced solutions can be freeze-dried.
- the freeze-dried solutions can be dissolved again in water and retain, surprisingly enough, their advantageous properties. This allows a long storage time of the active ingredient.
- the aqueous solutions of the perfluoroalkyl-containing substances are administered by interstitial/intracutaneous injection or intravenous injection at one or more injection sites.
- the administration volume relates to the species and form of administration between 0.1 ml and 30 ml, and the administered dose is preferably between 0.1 ⁇ mol/kg and 10 ⁇ mol/kg of body weight, relative to the dye.
- the galenic formulation After the galenic formulation is injected, light from the corresponding spectral range is irradiated for electronic stimulation of the dye that is used in the tissue.
- the reflected stimulation light or the fluorescence radiation that is emitted by the dye is recorded.
- fluorescence can be detected and evaluated spectrally and/or by phase selection, as well as in a steady-state manner and/or in a time-resolved manner.
- the fluorescence images that are obtained can be produced at the same time as the white light images and are depicted above one another in a figure for data evaluation. In the case of intraoperative diagnosis, the staining can be observed visually in addition for fluorescence detection.
- Synthesis is generally carried out starting from 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1-(4-sulfobutyl)-2,3,3-trimethyl-5-carboxy-3H-indolenine (Cytometry 10, 11-19, 1989, Talanta 39, 505-510, 1992).
- the synthesis is generally carried out starting from 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1,2,3,3-tetramethyl-5-carboxy-3H-indolium iodide (Cytometry 10, 11-19, 1989, Talanta 39, 505-510, 1992).
- the synthesis is carried out from 1 to 2 by activation of carboxylic acid and reaction with 1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecylamine (5) to 7 and 8, and by reaction with N-(2,3-dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amine (6) to 9 and 10.
- the synthesis of 5 and is described in DE 199 14 101.
- a solution of 0.5 mmol of dye 1 or 2 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.29 g (0.55 mmol) of 5 and 0.6 mmol of triethylamine in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 2 hours at room temperature.
- a solution of 0.5 mmol of dye 1 or 2 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.37 g (0.65 mmol) of 6 in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 18 hours at room temperature.
- the synthesis that is embodied in the example is carried out from 3 or 4 by activation of the carboxylic acid and reaction with 1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecylamine (5) to 11 and 12, and by reaction with N-(2,3-dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amine (6) to 13 and 14.
- a solution of 0.5 mmol of dye 3 or 4 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.29 g (0.55 mmol) of 5 and 0.6 mmol of triethylamine in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 2 hours at room temperature.
- a solution of 0.5 mmol of dye 1 or 2 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.37 g (0.65 mmol) of 6 in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 18 hours at room temperature.
- a dialysis to separate free dyes is performed (Amicon cell, cut-off 10,000, dialysis volumes 5 ⁇ 100 ml).
- the product solution is set at a volume of 5 ml (20 mmol/l) of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane) with water.
- Gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7-(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane for production, see DE 196 03 033, Example 1
- a stirred suspension of 141.0 g (289 mmol) of the title compound of Example Ab) in 200 ml of dioxane is mixed at room temperature and with simultaneous vigorous stirring in portions with a total of 238.5 g (4.26 mol) of finely powdered potassium hydroxide powder.
- the reaction mixture is mixed with another 200 ml of dioxane, and the suspension that is thus obtained is subsequently heated to boiling and mixed drop by drop at this temperature with a total of 372 ml (3.128 mol) of benzyl bromide over a period of two hours. After a reaction time of 4 hours at 110° C.
- reaction mixture is slowly poured into a total of 2.5 liters of ice water for the purpose of working-up, and the water phase is subsequently completely extracted with diethyl ether.
- the ether phase that is thus obtained is washed and the same is subsequently dried on sodium sulfate, salt is suctioned out, and the diethyl ether is removed in a vacuum.
- Excess benzyl bromide is then quantitatively distilled off from the reaction mixture in an oil pump vacuum at an oil bath temperature of 180° C.
- the resinous-oily residue that is thus obtained is purified on silica gel with use of ethyl acetate/hexane (1:10) as an eluant.
- reaction solution that is thus obtained is mixed at ⁇ 5° C. with a solution of 22.7 g (110 mmol) of dicyclohexylcarbodiimide, dissolved in 100 ml of tetrahydrofuran, and then stirred at ⁇ 5° C. for two more hours. After the reaction solution has thawed, it is stirred at room temperature for another 12 hours, precipitated dicyclohexylurea is filtered out, and the filtrate that is obtained is evaporated to the dry state in a vacuum. The remaining residue is taken up in 600 ml of ethyl acetate and washed twice with 300 ml of saturated sodium bicarbonate solution each as well as twice with 300 ml of water each.
- the reaction solution is slowly poured into 1.5 liters of ice water and then exhaustively extracted with diethyl ether.
- the combined diethyl ether phases are subsequently washed twice with 600 ml of saturated sodium bicarbonate solution each and twice with 800 ml of water each.
- the organic phase is dried on sodium sulfate, salt is suctioned out, and the solvent is removed in a vacuum.
- the remaining oily residue is purified on silica gel with use of ethyl acetate/hexane (1:5) as an eluant.
- the remaining residue is taken up in 300 ml of dimethyl sulfoxide, and 12.65 g (93.8% of theory) of the above-mentioned title compound is obtained as a colorless and crystalline powder from the product solution that is thus obtained by mixing with 750 ml of a mixture that consists of equal parts of dimethyl ether and ethyl acetate after the precipitated solid is suctioned off.
- the above-mentioned title compound is present as an ⁇ / ⁇ -anomer mixtures, whereby the ratio relative to the two possible anomers was determined at about 1:1.2 by 1 H-NMR-spectroscopic studies. Accordingly, the title compound is an almost approximately evenly divided ⁇ / ⁇ -anomer mixture.
- a stirred suspension of 100.0 g (204.96 mmol) of the title compound of Example IIIb) in 150 ml of dioxane is mixed at room temperature and with simultaneous, vigorous stirring in portions with a total of 169.14 g (3.02 mol) of finely powdered potassium hydroxide powder.
- the reaction mixture is mixed with another 150 ml of dioxane, and the suspension that is thus obtained is subsequently heated to boiling and mixed drop by drop at this temperature with a total of 264 ml (2.218 mol) of benzyl bromide over a period of two hours. After a reaction time of 4 hours at 110° C.
- reaction mixture is slowly poured into a total of 2.0 liters of ice water for the purpose of working-up, and the water phase is subsequently completely extracted with diethyl ether.
- the ether phase that is thus obtained is washed and said phase is subsequently dried on sodium sulfate, salt is suctioned out, and the diethyl ether is removed in a vacuum.
- Excess benzyl bromide is then quantitatively distilled off from the reaction mixture in an oil pump vacuum at an oil bath temperature of 180° C. The remaining oily residue that is thus obtained is purified on silica gel with use of ethyl acetate/hexane (1:10) as an eluant.
- the remaining residue is taken up in 250 ml of ethyl acetate and washed twice with 300 ml of saturated sodium bicarbonate solution each and once with 400 ml of water. After the organic phase is dried on sodium sulfate, salt is suctioned out, and the ethyl acetate is removed in a vacuum. The remaining oily residue is purified on silica gel with use of dichloromethane/hexane/2-propanol (10:5:1) as an eluant.
- 6-[1-O- ⁇ -D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide was dissolved in ethanol, mixed with a solution of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane in water, and the mixture was treated in an ultrasound bath after dye was added, and the procedure was as in Example 13.
- the galenical formulations that are produced according to the instructions of Examples 13 to 15 are freeze-dried according to common procedures.
- the blue-colored lyophilizates are stored for 5 days at room temperature, then resuspended by shaking in 5-10 ml of water and subjected to dialysis as described above.
- the dye content after dialysis was determined photometrically and in all cases amounted to 96-99% relative to the content before freeze-drying and resuspension.
- the imaging properties of the formulations according to the invention were studied in vivo in guinea pigs.
- a formulation was administered interstitially/intracutaneously, and the concentration in regional lymph nodes was observed in a period of 0 to 120 minutes.
- the fluorescence of the substances was stimulated by irradiation of the animals with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser.
- the fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 1 shows near-infrared fluorescence images of a guinea pig after interstitial/intracutaneous administration of formulations with 5 mol % of dye 8/95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane.
- 0.1 ml of a stock solution with 1 mmol/L of 8 was injected into a skin fold between the toes of the right rear extremity, and the final concentration was 0.3 ⁇ mol/kg of 8.
- the regional lymph nodes were prepared in the area of the administration site. It was observed that these lymph nodes have a green coloring because of the accumulation of the substance according to the invention. This coloring can be used for the intraoperative diagnosis for the identification of the draining lymph nodes of a certain tissue area and for differentiating the lymph nodes from the surrounding tissue.
- FIG. 2 shows two inguinal lymph nodes of guinea pigs after interstitial/intracutaneous administration of a formulation with 5 mol % of dye 8/95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (A, B) and a lymph node of an untreated guinea pig ex vivo (C).
- a formulation with 5 mol % of dye 8 resulted in a clearly visible green-coloring of the lymph nodes after interstitial administration.
- lymph nodes were prepared after the lymphography and deep-frozen at ⁇ 80° C. Sections with a 5 ⁇ m thickness were produced on a freezing microtome.
- the evaluation was carried out on a Zeiss Axiovert 135-fluorescence microscope, which was equipped with a Cy 7-(excitation filter HQ710/70 nm, emission filter 810/90 nm, beam splitter 750 nm LP). From all the preparations, white light and fluorescence images were recorded with a CCD camera (Princeton Instruments RTE/CCD-576) and stored digitally.
- FIG. 3 shows a bright-field ( 1 a) and a near-infrared-fluorescence image ( 1 b) of a frozen section of a popliteal guinea pig lymph node four hours after interstitial administration of a formulation with 5 mol % of dye 8/95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane.
- Bright field Lens 2.5 ⁇ . Exposure 0.02 seconds, no accumulation. Tube enlargement 0.6.
- NTR Lens 2.5 ⁇ . Exposure 1 second, accumulation 5 ⁇ , tube enlargement 0.6, Cy7-set of filters.
- the fluorescence of the substances was stimulated by irradiation of the lymph nodes with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser.
- the fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 4 shows a fluorescence image of lymph nodes 5 hours after intravenous administration of a formulation with 5 mol % of dye 8 and 95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5- ⁇ 4-perfluorooctylsulfonyl-piperazin-1-yl ⁇ -pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane. Shown are the axillary (a, a′), inguinal (b, b′) and popliteal (c, c′) lymph nodes of the animal. All lymph nodes showed a clear fluorescence signal.
- the test animal was sacrificed and opened abdominally. Based on the fluorescence image, the lymph nodes can be localized in situ and the lymph tracts can be visualized. The identification of the lymph nodes in situ is also visually possible by a green coloring, which is caused after interstitial administration of the formulation.
- the fluorescence of the substances was stimulated by irradiation of the abdominally-opened animal with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser.
- the fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 5 shows a fluorescence image of an abdominally-opened rat five hours after interstitial administration of a formulation with 5 mol % of dye 8 and 95 mol % of mannose in a skin fold between the toes of the right rear extremity.
- the axillary and the inguinal lymph nodes and a connected lymph tract are visualized based on a fluorescence signal.
- the fluorescence of the substances was stimulated by irradiation of the lymph nodes with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser.
- the fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 6 shows a fluorescence image of lymph nodes five hours after interstitial administration of a formulation with 5 mol % of dye 8 and 95 mol % of 6-[1-O- ⁇ -D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide.
- lymph nodes of the animal Shown are the mandibular (m, m′), axillary (a, a′), mesenteric (mes), iliac (il, il′), inguinal (in, in′), gluteal (g, g′) and popliteal (p, p′) lymph nodes of the animal.
- Most lymph nodes of the right (administered) side of the body showed a fluorescence signal, while no lymph nodes of the left side of the body (in each case identified with ′) had a fluorescence signal.
- the fluorescence-labeled lymph nodes were greenish-colored because of the accumulation of substances.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Abstract This invention describes galenical formulations that contain perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances. The new formulations are suitable as, i.a., contrast media for near-infrared diagnosis.
Description
- The invention relates to the field of galenical formulations, which are used in particular as contrast media for the visualization of lymph nodes. The invention relates to the subject that is characterized in the claims, namely new galenical formulations that contain perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances.
- Malignant tumors metastasize heaped in regional lymph nodes, whereby several lymph node stations can also be involved. Thus, lymph node metastases are found in about 50-69% of all patients with malignant tumors (Elke, Lymphographie [Lymphography], in: Frommhold, Stender, Thurn (eds.), Radiologische Diagnostik in Klinik und Praxis [Radiological Diagnosis in Clinical Studies and Practice], Volume IV, Thieme Verlag Stuttgart, 7th Ed., 434-496, 1984). The diagnosis of a metastatic attack of lymph nodes is of great importance with respect to the therapy and prognosis of malignant diseases. With the modern imaging methods (CT, US, and MRT), lymphogenous metastasis sites of malignant tumors are detected only inadequately, since in most cases, only the size and the shape of the lymph node can be used as a diagnostic criterion. Thus, small metastases in non-enlarged lymph nodes (<2 cm) are not distinguished from lymph node hyperplasias without a malignant attack (Steinkamp et al., Sonographie und Kernspintomographie: Differentialdiagnostik von reaktiver Lymphknotenvergröberung und Lymphknotenmetastasen am Hals [Sonography and Nuclear Spin Tomography: Differential Diagnosis of Reactive Lymph Node Enlargement and Lymph Node Metastases on the Neck], Radiol. Diagn. 33: 158, 1992).
- It would be desirable to distinguish between lymph nodes with metastatic attack and hyperplastic lymph nodes with the aid of specific contrast media. In this case, the contrast medium could be adminisitered intravasally or interstitially/intracutaneously (see above Siefert, H. M. et al., Lymphology 13, 150-157, 1980). The interstitial/intracutaneous administration has the advantage that the substance is transported directly from the scattering focus (e.g., primary tumor) by the corresponding lymph tract into the potentially related regional lymph node stations. Likewise, a high concentration of the contrast medium in the lymph nodes can be achieved with a low dose. Such markers that are to be administered interstitially were mainly used in the nuclear-medicine evaluation (with use of radioactive particles, such as, e.g.,198Au-colloid). Nuclear-medicine methods have only a very inadequate spatial resolution, however, in contrast to nuclear spin tomography with its high spatial resolution in the range of fractions of a millimeter. The direct x-ray-lymphography (injection of an oily contrast medium suspension in a prepared lymph vessel) is an invasive method that is used very rarely and that can visualize only a few lymph outflow stations. Fluorescence-labeled dextrans are also used experimentally in animal experiments to be able to observe the lymph outflow after their interstitial administration. All commonly used markers for the visualization of lymph tracts and lymph nodes after interstitial/intracutaneous administration have in common the fact that they are substances with a particulate nature (“particulates,” e.g., emulsions and nanocrystal suspensions) or large polymers (see above, WO 90/14846). The previously described preparations have proven to be of value, however, based on their inadequate local and systemic compatibility as well as their small lymph passageway, which produces an inadequate diagnostic efficiency, in most cases unsuitable for indirect lymphography.
- There is generally a greet need, therefore, for lymph-specific contrast-media with suitable pharmaceutical and pharmacological properties. In the pharmaceutical properties, focus is placed first on the highest possible contrast medium concentration and an adequate stability. In the case of the pharmacological properties, and in addition to a diagnostically relevant lymph concentration that is as uniform as possible over several (or in the case of intravenous administration over all) lymph stations, focus is placed mainly on a quick and complete excretion of the contrast medium to avoid an unnecessary load of the entire organism. Moreover, corresponding preparations must have at their disposal an adequate local and acute compatibility.
- With respect to the application in radiological practice and in addition to as simple an application as possible of corresponding preparations, the quick “start-up” of the preparations is of central importance. Thus, if at all possible, it should be possible to perform imaging within a few hours after the administration of the contrast media.
- Contrast media that are suitable for the visualization of lymph nodes in nuclear spin tomography are described in German Laid-Open Specification DE 196 03 033. There, perfluoroalkyl-containing metal complexes are disclosed, which are preferably used as lymphographic agents (see FIG. 1 of DE 196 03 033). Similar metal complexes that are suitable especially as blood-pool agents are described in German Laid-Open Specification DE 197 29 013.
- A process for in-vivo diagnosis with use of NIR radiation is described in International Application WO 96/17628. Such diagnostic processes are at present under development. The contrast media that are described in this document are not suitable for visualizing the lymph nodes. There is therefore a need for suitable lymph-specific contrast media for these new diagnostic processes.
- The object of this invention is therefore to make available new galenical formulations that are suitable as contrast media especially for the visualization of lymph nodes in the above-mentioned new diagnostic processes, and that-meet the above-mentioned pharmaceutical and pharmacological requirements.
- This object is achieved by the galenical formulations of this invention.
- The new galenical formulations contain perfluoroalkyl-containing dye molecules, which can be used as contrast media in near-infrared diagnosis. The dyes satisfy certain photophysical and chemical requirements. They have high absorption coefficients and high fluorescence quantum yields to produce an effective signal even at the lowest tissue concentrations. The absorption maxima overlap a wide spectral range in a freely selectable manner. For detection in lower tissue layers (several centimeters under the surface), the spectral range between 600 and 900 nm is essential, while absorption wavelengths of 400 to 600 nm are sufficient for surface detection. The dyes further have a high chemical stability and photostability. When using light for fluorescence stimulation, the essential problem is the limited penetration depth of the light, which lies in the submillimeter range in the VIS but can be in the centimeter range in the NIR. With respect to the penetration depth, detection processes in surface tissue diseases, as well as soft tissues, are unproblematic. Since a considerable number of tissue changes (e.g., breast tumors, skin tumors, lymph node changes) are located on the surface, optical diagnostic processes in addition to the conventional methods are offered to perform a tissue differentiation based on different absorption and fluorescence patterns. In this case, the pronounced diffusion of light, which obtains increasing influence with growing tissue thickness, reduces both the resolution and the contrast of an optical image. Dyes that are used as so-called optical contrast media and are concentrated in the tissues that are to be detected can result in principle in an increase of the diagnostic value of optical detection processes, in which they increase the absorption of the tissue and provide an additional measurement signal with the dye-specific fluorescence, which can be detected arbitrarily often in front of a low tissue background with high sensitivity.
- Preferred are dyes from the following classes:
- Polymethine dyes, such as, e.g., cyanine dyes, squarilium dyes, croconium dyes, oxonol dyes, merocyanine dyes, cryptocyanine dyes;
- xanthine dyes, such as, e.g., fluorescein and rhodamine and derivatives thereof;
- heteroaromatic, cationic dyes, such as, e.g., oxazines, phenoxazines, thiazines, phenothiazines.
- The new perfluoroalkyl-containing dye molecules are compounds of general formula I
- Rf-L-A (I)
- in which Rf represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms, L stands for a linker, and A stands for a dye molecule.
- Linker L is a direct bond or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COO, —SO3 groups and/or optionally is interrupted by one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR—, —NRCO—, —SO2—, —NH—, —NR groups or a piperazine, whereby R stands for a C1 to C10 alkyl radical, which optionally is substituted with one or more OH groups and/or is interrupted by one or more oxygen atoms.
- Dye molecule A is a dye from the class of the polymethine dyes, xanthine dyes or the heteroaromatic cationic dyes. Dye molecule A is preferably a cyanine dye, squarilium dye, croconium dye, oxonol dye, merocyanine dye, cryptocyanine dye, fluorescein dye, rhodamine dye, oxazine dye, phenoxazine dye, thiazine dye or phenothiazine dye. Especially preferably dye molecule A is a molecule according to general formula II:
- in which
-
-
- whereby R1 and R2 represent a C1-C4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1- C50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated, cyclic C5-C6 units or bicyclic C10 units, and whereby the C1-C50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups,
- R3 stands for a radical —COOE1, —CONE1E2, —NHCOE1, —NHCONHE1, —NE1E2, —OE1, —OSO3E1, —SO3E1, —SO2NHE1, —E1,
- whereby E1 and E2, independently of one another, represent a hydrogen atom, a C1-C4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated cyclic C5-C6 units or bicyclic C10 units, and whereby the C1-C50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups, and/or is substituted with 0 to 5 hydroxy groups,
- and whereby R4 stands for a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, or a branched or straight-chain C1-C10 alkyl chain,
- b means a number 2 or 3,
- and X and Y, independently of one another, mean O, S, —CH═CH— or C(CH3)2.
-
- in which
- p stands for 1, 2 or 3,
- R1 and R2, independently of one another, stand for a 4-sulfobutyl, 3-sulfopropyl, 2-sulfoethyl-, 3-methyl-3-sulfopropyl, methyl, ethyl or propyl radical, and
- R3 stands for hydrogen, for a radical —COOE1, —CONE1E2, —NHCOE1, —NHCONHE1, —NE1E2, —OE1, —OSO3E1, —SO3E1, —SO2NHE1,
- whereby E1 and E2, independently of one another, stand for a hydrogen atom or for a methyl, ethyl or a C3-C6 alkyl radical, which is interrupted by 0 to 2 oxygen atoms and/or by 0 to 1 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups or stands for a poly(oxyethylene)glycol radical with 2 to 30 —CH2CH2O units.
- The galenical-formulations according to the invention further contain other perfluoroalkyl-containing compounds, e.g., perfluoroalkyl-containing metal complexes. Perfluoroalkyl-containing metal complexes and their production were already described in the German Laid-Open Specifications DE 196 03 033, DE 197 29 013 and WO 97/26017. These perfluoroalkyl-containing metal complexes are compounds of general formula XIV
- Rf-M (XIV)
- in which Rf represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms, and M is a molecule portion that contains 1-6 metal complexes.
-
- whereby p1 means the
numbers 0 to 10, q and u, independently of one another, mean thenumbers 0 or 1, and - R1 means a hydrogen atom, a methyl group, a —CH2—OH group, a —CH2—CO2H group or a C2-C15 chain, which optionally is interrupted by 1 to 3 oxygen atoms, 1 to 2>CO groups or an optionally substituted aryl group and/or is substituted with 1 to 4 hydroxyl groups, 1 to 2 C1-C4 alkoxy groups, 1 to 2 carboxy groups,
-
- optionally substituted aryls and/or is interrupted by these groups and/or is optionally substituted with 1 to 3 —OR1 groups, 1 to 2 oxo groups, 1 to 2 —NH—COR1 groups, 1 to 2 —CONHR1 groups, 1 to 2 (—CH2)p—CO2H groups, 1 to 2 groups —(CH2)p—(O)q—CH2CH2—RF,
- whereby
- R1, RF and p and q have the above-indicated meanings, and
- T means a C2-C10 chain, which optionally is interrupted by 1 to 2 oxygen atoms or 1 to 2 —NHCO groups.
- In this case, metal complex M″ stands for the following metal complexes:
-
- in which R3, Z1 and Y are independent of one another, and
- R3 has the meaning of R1 or —(CH2)m-L-RF, whereby m is 0, 1 or 2, and L and RF have the above-mentioned meaning,
- Z1, independently of one another, mean a hydrogen atom or a metal ion equivalent of atomic numbers 21-29, 39, 42, 44 or 57-83,
-
- whereby Z1, L, RF and R3 have the above-mentioned meanings,
-
- in which R3 and Z1 have the above-mentioned meanings, and R2 has the meaning of R1,
-
- in which Z1 has the above-mentioned meaning,
-
- in which Z1 has the above-mentioned meaning, and o and q stand for
numbers 0 or 1, and yields the sum o+q=1, -
- in which Z1 has the above-mentioned meaning,
-
- in which Z1 and Y have the above-mentioned meanings,
-
- in which R3 and Z1 have the above-mentioned meanings, and R2 has the above-mentioned meaning of R1,
-
- in which R3 and Z1 have the above-mentioned meanings,
-
- in which R3 and Z1 have the above-mentioned meanings,
-
- in which Z1, p and q have the above-mentioned meaning, and R2 has the meaning of R1,
-
- in which L, RF and Z1 have the above-mentioned meanings,
-
- in which Z1 has the above-mentioned meaning.
- Such compounds and production thereof are described in German Laid-Open Specification DE 196 03 033 A1 and in International Patent Application WO 97/26017.
-
- whereby
- q1 is a
number 0, 1, 2 or 3, - K stands for a complexing agent or metal complex or salts thereof of organic and/or inorganic bases or amino acids or amino acid amides,
- X is a direct bond for the perfluoroalkyl group, a phenylene group or a C1-C10 alkyl chain, which optionally contains 1-15 oxygen atoms, 1-5 sulfur atoms, 1-10 carbonyl groups, 1-10 —(NR) groups, 1-2 NRSO2 groups, 1-10 CONR groups, 1 piperidine group, 1-3 SO2 groups, 1-2 phenylene groups or optionally is substituted by 1-3 radicals RF, in which R stands for a hydrogen atom, a phenyl, benzyl or a C1-C15 alkyl group, which optionally contains 1-2 NHCO groups, 1-2 CO groups, 1-5 oxygen atoms and optionally is substituted by 1-5 hydroxy, 1-5 methoxy, 1-3 carboxy, 1-3 RF radicals,
-
- in which
- R1a is a hydrogen atom, a phenyl group, a benzyl group or a C1-C7 alkyl group, which optionally is substituted with a carboxy group, a methoxy group or a hydroxy group,
- Z1 is a direct bond, a polyglycol ether group with up to 5 glycol units or a molecule portion of general formula XXIX
- —CH(R2a)— (XXIX)
- in which R2a is a C1-C7 carboxylic acid, a phenyl group, a benzyl group or a —(CH2)1-5—NH—K group,
- α represents the binding to the nitrogen atom of the skeleton chain, β represents the binding to the complexing agent or metal complex K,
- and in which variables k and m stand for natural numbers between 0 and 10, and 1 stands for 0 or 1, and whereby
- G is a CO or SO2 group.
- Such compounds and the production thereof are described in German Laid-Open Specification DE 197 29 013 A1.
-
- in which
- N represents a nitrogen atom,
- A1 means a hydrogen atom, a straight-chain or branched C1-C30 alkyl group, which optionally is interrupted by 1-15 oxygen atoms and/or optionally is substituted with 1-10 hydroxy groups, 1-2 COOH groups, a phenyl group, a benzyl group and/or 1-5 —OR4 groups, with R4 in the meaning of a hydrogen atom or a C1-C7 alkyl radical, or B1-RF,
- B1 means a straight-chain or branched C1-C30 alkylene group that optionally is interrupted by 1-10 oxygen atoms, 1-5 —NH—CO groups, 1-5 —CO—NH groups, by a phenylene group (that is optionally substituted by a COOH group), 1-3 sulfur atoms, 1-2 —N(B2)—SO0 groups, and/or 1-2 —SO2—N(B2) groups with B2 in the meaning of A1, an NHCO group, a CONH group, an N(B2)—SO2group, or an —SO2— N(B2) group and/or optionally is substituted with radical RF,
- and in which a represents the binding to metal complex M2, and b represents the binding to perfluoroalkyl group RF.
-
- whereby R1 stands for a hydrogen atom or a metal ion equivalent of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,
- R2 and R3 stand for a hydrogen atom, a C1-C7 alkyl group, a benzyl group, a phenyl group, —CH2OH or —CH 2—OCH3,
- U stands for radical L, whereby L and U, independently of one another, can be the same or different, however.
- Such compounds and their production are described in the German patent application with file number 199 14 101.0 as well as in the examples below.
- Especially preferred are metal complexes in which the central atom is a gadolinium atom (atomic number 64). Metal complexes with cyclic chelating agents are preferred compared to those with open-chain chelating agents.
- Especially preferred gadolinium complexes are the gadolinium complex of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see WO 97/26017, Example 33),
- the gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-oxa-10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,17-heptadecafluoroheptadecyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see DE 196 03 033, Example 2),
- 1,4,7-tris{1,4,7-tris(N-carboxylatomethyl)-10-(N-1-methyl-3,6-diaza-2,5,8-trioxooctane-1,8-diyl)-1,4,7,10-tetraazacyclododecane, Gd-complex}-10-(N-2H,2H,4H,4H,5H,5H-3-oxa-perfluoro-tridecanoyl)-1,4,7,10-tetraazacyclododecane (for production, see DE 197 29 013, Example 1),
- 1,4,7-tris{1,4,7-tris[(N-carboxylatomethyl)]-10-[N-1-methyl-3-aza-2,5-dioxopentam-1,5-diyl]-1,4,7,10-tetraazacyclododecane, Gd complex}-10-[2-(N-ethyl-N-perfluorooctylsulfonyl)-amino]-acetyl-1,4,7,10-tetraazacyclododecane (for production, see DE 197 29 013, Example 12),
- the gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see DE 196 03 033, Example 1),
- 1,4,7-tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(2,3-dihydroxy-propyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide}-1,4,7,10-tetraazacyclododecane, gadolinium complex (for production see examples),
- 1,4,7-tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex (for production see examples),
- 1,4,7-tris(carboxylatomethyl)-10-{(3-aza-4-oxo-hexan-5-ylic)-acid-[N-3,6,9,12,15-pentaoxa)-hexadexyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl]-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex (for production, see examples),
- and 1,4,7-tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(5-hydroxy-3-oxa-pentyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex (for production, see examples).
- Instead of the perfluoroalkyl-containing metal complexes, other perfluoroalkyl-containing compounds can also be contained in the galenical formulations according to the invention. Such compounds are compounds of general formula XXXII
- Rf-L2-G1 (XXXII)
- in which Rf represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms, L2 stands for a linker, and G1 stands for a hydrophilic group.
- Linker L2 is a direct bond, an —SO2 group or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COO−, —SO3 groups and/or optionally contains one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR″—, —NR″CO—, —SO2—, —PO4—, —NH—, —NR″ groups, an aryl ring or a piperazine, whereby R″ stands for a C1 to C20 alkyl radical, which in turn can contain one or more O-atoms and/or can be substituted with —COO− or SO3 groups. Hydrophilic group G1 stands for a monosaccharide or disaccharide, one or more adjacent —COO− or —SO3 groups, a dicarboxylic acid, an isophthalic acid, a picolinic acid, a benzenesulfonic acid, a tetrahydropyrane dicarboxylic acid, a 2,6-pyridinedicarboxylic acid, a quaternary ammonium ion, an aminopolycarboxylic acid, an aminodipolyethyleneglycolsulfonic acid, an aminopolyethylene glycol group, an SO2—(CH2)2—OH group, a polyhydroxyalkyl chain with at least two hydroxyl groups or one or more polyethylene glycol chains with at least two glycol units, whereby the polyethylene glycol chains are terminated by an —OH or —OCH3 group. Such substances are already known (see, e.g., Tetrahedron Letters, Vol. 36, No. 4, pp. 539-542, 1995). The synthesis of some of these compounds is described in detail in the examples below. Those compounds that contain a monosaccharide as hydrophilic group G1 are preferably used.
- Especially preferred perfluoroalkyl-containing compounds contain a perfluoroalkyl radical Rf with 6 to 12 carbon atoms, a linker L2, which represents an —SO2 group or a straight-chain or branched carbon chain with up to 20 carbon atoms, which in turn contains one or more —O—, —CO—, —CONH—, —NHCO—, —CONR″—, NR″CO—, —SO2 groups or a piperazine, in which R″ has the above-indicated meaning, and a monosaccharide as hydrophilic group G1.
- It is also possible to produce galenical formulations with three components and to use the latter as contrast media for the visualization of lymph nodes. Such formulations are described in detail in the examples below.
- The substance mixtures according to the invention can be present in dissolved form in a solvent. The solvent is preferably water. The proportion of the perfluoroalkyl-containing dye molecule is between 0.1 and 10 mol % relative to the total amount of perfluoroalkyl-containing substances, preferably between 1 and 10 mol %. Preferred are mixtures that consist of perfluoroalkyl-containing dye molecules and other perfluroalkyl-containing compounds, in which-the perfluoroalkyl chains have a length of 6 to 12 carbon atoms. Especially preferred are mixtures in which both the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds have a perfluoroalkyl chain with 8 carbon atoms.
- The new galenical formulations show surprising advantages in their use as contrast media. Galenical formulations that consist of perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances can be produced in a wide variety. These formulations are suitable for fluorescence detection and visually detectable staining of lymph nodes after interstitial or intravenous administration.
- Compared to the already known contrast media for visualization of the lymph nodes, they show an improved compatibility and an almost complete excretion. The local compatibility further is also higher than in the previously known contrast media, and the new formulations simultaneously show a higher organ specificity. The concentration in the lymph nodes is higher than in the known contrast media for lymphography. If perfluoroalkyl-containing dye molecules and perfluorine-containing metal complexes are used simultaneously, it is possible to use various diagnostic processes in succession. In addition to the near-infrared diagnosis, e.g., computer or nuclear spin tomography can also be performed.
- Another advantage consists in the fact that the lymph nodes assume a characteristic coloring. In addition to the NIR diagnosis, this allows an intraoperative fluorescence diagnosis of the lymph node morphology and lymph tract permeability as well as a fluorescence-supported removal of biopsies. In this case, the fluorescence-supported detection of the so-called sentinel lymph node is especially important. The sentinel lymph node is the first lymph node that drains the lymphs of a tumor area and thus also the first lymph node that is affected in a metastasis attack of lymph nodes.
- The fluorescence-supported detection of these lymph nodes is carried out very much more simply than, e.g., the detection with the aid of radiopharmaceutical agents, since the detection of x-ray radiation is always more difficult than direct detection of fluorescence radiation. In addition, the stained lymph nodes are to be made visible, since the lymph nodes also can assume a characteristic coloring in the case of the corresponding dosage of the compounds according to the invention.
- The dye molecules are produced in a way that is similar to methods that are known in the literature and then coupled with perfluoroalkyl derivatives. Preferred are dyes from the above-mentioned classes, which contain carboxyl groups or isothiocyanate groups. Especially preferred are those dyes that contain carboxyl groups, which after activation with use of standard reagents are reacted with amino groups that contain perfluoroalkyl derivatives with the formation of an amide group. Literature for synthesis of polymethine dyes: Bioconjugate Chem. 4, 105-111, 1993; Bioconjugate Chem. 7, 356-62, 1996; Bioconjugate Chem. 8, 751-56, 1997; Cytometry 10, 11-19, 1989 and 11, 418-30, 1990; J. Heterocycl. Chem. 33, 1871-6, 1996; J. Org. Chem. 60, 2391-5, 1995; Dyes and Pigments 17, 19-27, 1991, Dyes and Pigments 21, 227-34, 1993; J. Fluoresc. 3, 153-155, 1993; Anal. Biochem. 217, 197-204, 1994; U.S. Pat. No. 4,981,977; U.S. Pat. No. 5,688,966; U.S. Pat. No. 5,808,044; WO 97/42976; WO 97/42978; WO 98/22146; WO 98/26077; EP 0800831.
- The production of the galenical formulations is carried out in that the perfluoroalkyl-containing dye molecule (component A) and the other perfluoroalkyl-containing substance (component B) are weighed and are dissolved in a suitable solvent. An especially suitable solvent is water. As already mentioned above, the proportion of the perfluoroalkyl-containing dye molecule is between 1 and 10 mol % relative to the total amount of perfluoroalkyl-containing substances. The concentration of the solution is preferably between 0.1 mmol/L and 20 mmol/L relative to the dye. This solution is then added in excess to commonly used galenical additives, such as, e.g., buffer solutions and the Ca-salt of the complexing agent. At 10 to 100° C., the solutions are stirred vigorously. As an alternative, the solutions can be treated at 10 to 100° C. in an ultrasound bath. Another alternative consists in that the solutions are treated with microwaves.
- In substances that do not dissolve in water as individual components, it has proven advantageous to add a solubilizer, such as alcohol (e.g., methanol or ethanol) or another water-miscible solvent and then to distill off the latter slowly. The distillation can take place under vacuum. The residue is then dissolved in water, and the solution is filtered. It is also possible to dissolve each component per se separately in a solvent, then to join them and to proceed further as above.
- Such produced solutions can be freeze-dried. The freeze-dried solutions can be dissolved again in water and retain, surprisingly enough, their advantageous properties. This allows a long storage time of the active ingredient.
- With use as a contrast medium for the visualization of the lymph nodes, the aqueous solutions of the perfluoroalkyl-containing substances (at a concentration of between 0.1 mmol/L and 20 mmol/L relative to the dye, see above) are administered by interstitial/intracutaneous injection or intravenous injection at one or more injection sites. The administration volume relates to the species and form of administration between 0.1 ml and 30 ml, and the administered dose is preferably between 0.1 μmol/kg and 10 μmol/kg of body weight, relative to the dye.
- After the galenic formulation is injected, light from the corresponding spectral range is irradiated for electronic stimulation of the dye that is used in the tissue. The reflected stimulation light or the fluorescence radiation that is emitted by the dye is recorded. Preferred are the methods in which the tissue irradiates over a large surface and the fluorescence radiation is triggered locally by recording with a CCD camera or the tissue areas that are to be formed are rastered with a fiber optic light guide, and the signals that are obtained are assembled by computer into a synthetic image. In this case, fluorescence can be detected and evaluated spectrally and/or by phase selection, as well as in a steady-state manner and/or in a time-resolved manner. The fluorescence images that are obtained can be produced at the same time as the white light images and are depicted above one another in a figure for data evaluation. In the case of intraoperative diagnosis, the staining can be observed visually in addition for fluorescence detection.
- The following examples explain the invention, without intending that it be limited to these examples.
- Synthesis is generally carried out starting from 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1-(4-sulfobutyl)-2,3,3-trimethyl-5-carboxy-3H-indolenine (Cytometry 10, 11-19, 1989, Talanta 39, 505-510, 1992).
- Synthesis of 1,1′-bis-(4-sulfobutyl)indodicarbocyanine-5-carboxylic acid. sodium salt (1)
- 1.2 g (4.1 mmol) of 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1.0 g (3.9 mmol) of malonaldehyde-bis-phenylimine-hydrochloride are stirred into 15 ml of acetic acid anhydride for 30 minutes at 120° C. and then cooled to room temperature with a water bath. Then, 1.4 g (4.2 mmol) of 1-(4-sulfobutyl)-2,3,3-trimethyl-5-carboxy-3H-indolenine, 1.2 g (14.6 mmol) of anhydrous sodium acetate, 15 ml of acetic acid anhydride and 6 ml of acetic acid are added in succession. The reaction mixture is heated for 1 hour to 120° C., the reaction solution is cooled and mixed with 100 ml of ether. The precipitated solid is filtered off. Chromatographic purification is carried out on RP-silica gel EUROPREP 60-30 C18 (Knauer), 60A, 20-45μ (eluant: water/MeOH, step gradient of 0% to 70% MeOH). Methanol is removed from the product-containing fractions in a rotary evaporator, and the fractions are then freeze-dried, yield: 1.8 g (66%), blue lyophilizate.
- Synthesis of 1,1′-bis-(4-sulfobutyl)indotricarbocyanine-5-carboxylic acid, sodium salt (2)
- 1.2 g (4.1 mmol) of 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1.1 g (3.9 mmol) of glutaconaldehyde-dianilhydrochloride are stirred in 15 ml of acetic acid anhydride for 30 minutes at 120° C. and then cooled to room temperature with a water bath. Then, 1.4 g (4.2 mmol) of 1-(4-sulfobutyl)-2,3,3-trimethyl-5-carboxy-3H-indolenine, 1.2 g (14.6 mmol) of anhydrous sodium acetate, 15 ml of acetic acid anhydride and 6 ml of acetic acid are added. The reaction mixture is heated for 1 hour to 120° C., the now blue solution is cooled and mixed with 100 ml of ether. The working-up and purification are carried out as described in Example 1, yield: 1.8 g (60%) of blue lyophilizate.
- The synthesis is generally carried out starting from 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1,2,3,3-tetramethyl-5-carboxy-3H-indolium iodide (Cytometry 10, 11-19, 1989, Talanta 39, 505-510, 1992).
- 1.2 g (4.1 mmol) of 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1.0 g (3.9 mmol) of malonaldehyde-bis-phenylimine-hydrochloride are stirred into 15 ml of acetic acid anhydride for 30 minutes at 120° C. and then cooled to room temperature with a water bath. Then, 1.6 g (4.6 mmol) of 1,2,3,3-tetramethyl-5-carboxy-3H-indolium iodide, 1.2 g (14.6 mmol) of anhydrous sodium acetate, 15 ml of acetic acid anhydride and 6 ml of acetic acid are added in succession. The reaction mixture is heated for 1 hour to 120° C., the now blue solution is cooled and mixed with 100 ml of ether. The precipitated solid is filtered off. A chromatographic purification of RP-silica gel EUROPREP 60-30 C18 (Knauer), 60A, 20-45μ is carried out (eluant: water/MeOH, step gradient of 30% to 90% MeOH). Methanol is removed from the product-containing fractions in a rotary evaporator and then freeze-dried, yield: 0.9 g (42%), blue lyophilizate.
- 1.2 g (4.1 mmol) of 1-(4-sulfobutyl)-2,3,3-trimethyl-3H-indolenine and 1.1 g (3.9 mmol) of glutaconaldehyde-dianilhydrochloride are stirred in 15 ml of acetic acid anhydride for 30 minutes at 120° C. and then cooled to room temperature with a water bath. Then, 1.6 g (4.6 mmol) of 1,2,3,3-tetramethyl-5-carboxy-3H-indolium iodide, 1.2 g (14.6 mmol) of anhydrous sodium acetate, 15 ml of acetic acid anhydride and 6 ml of acetic acid are added. The reaction mixture is heated for 1 hour to 120° C., the reaction solution is cooled and mixed with 100 ml of ether. The working-up and purification are carried out as described in Example 3. Yield: 1.4 g (62%) of blue lyophilizate.
- The synthesis is carried out from 1 to 2 by activation of carboxylic acid and reaction with 1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecylamine (5) to 7 and 8, and by reaction with N-(2,3-dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amine (6) to 9 and 10. The synthesis of 5 and is described in DE 199 14 101.
# M (g/mol) 7 1182.0 5-{N-[2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9, 10,10,10-heptadecafluorodecyloxy)ethyl]- aminocarbonyl}-2-{7-[1,3-dihydro-3,3- dimethyl-1-(4-sulfobutyl)-2H-indol-2- ylidene]-1,3-pentadienyl}-3,3-dimethyl-1-(4- sulfobutyl)-3H-indolium, internal salt, sodium salt 8 1208.0 5-{N-[2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9, 10,10,10-heptadecafluoro-decyloxy)ethyl]- aminocarbonyl}-2-{7-[1,3-dihydro-3,3- dimethyl-1-(4-sulfobutyl)-2H-indol-2- ylidene[-1,3,5-heptatrienyl}-3,3-dimethyl-1- (4-sulfobutyl)-3H-indolium, internal salt, sodium salt 9 1256.1 5-{N-[2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9, 10,10,10-heptadecafluorodecyloxy)ethyl]-N- (2,3-dihydroxypropyl)aminocarbonyl}-2-{7- [1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)- 2H-indol-2-ylidene]-1,3-pentadienyl}-3,3- dimethyl-1-(4-sulfobutyl)-3H-indolium, internal salt, sodium salt 10 1282.1 5-{N-[2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9, 10,10,10-heptadecafluorodecyloxy)ethyl]-N- (2,3-dihydroxypropyl)aminocarbonyl}-2-{7- [1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)- 2H-indol-2-ylidene]-1,3,5-heptatrienyl}-3,3- dimethyl-1-(4-sulfobutyl)-3H-indolium, internal salt, sodium salt - A solution of 0.5 mmol of dye 1 or 2 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.29 g (0.55 mmol) of 5 and 0.6 mmol of triethylamine in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 2 hours at room temperature. After 50 ml of hexane/50 ml of ethyl acetate is added, the precipitated solid is filtered off and chromatographically purified on RP-silica gel LiChroprep® RP-8 (Merck), 40-63μ (eluant: water/MeOH, step gradient of 20% to 80% MeOH); yields: 0.42 g (71%) of 7, 0.45 g (75%) of 8.
- A solution of 0.5 mmol of dye 1 or 2 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.37 g (0.65 mmol) of 6 in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 18 hours at room temperature. After 50 ml of hexane/50 ml of ethyl acetate is added, the precipitated solid is filtered off and purified chromatographically on RP-silica gel LiChroprep® RP-8 (Merck), 40-63μ (eluant: water/MeOH, step gradient of 20% to 80% MeOH); yields: 0.40 g (63%) of 9, 0.43 g (67%) of 10.
- The synthesis that is embodied in the example is carried out from 3 or 4 by activation of the carboxylic acid and reaction with 1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecylamine (5) to 11 and 12, and by reaction with N-(2,3-dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amine (6) to 13 and 14.
# M (g/mol) 11 1037.9 2-[5-(1-Ethyl)-1,3-dihydro-3,3-dimethyl-2H- indol-2-ylidene)-1,3-pentatrienyl]-5-{N-[2- (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10- heptadecafluorodecyloxy)ethyl]- aminocarbonyl}-3,3-dimethyl-1-(4-sulfobutyl)- 3H-indolium, internal salt, sodium salt 12 1063.9 2-[5-(1-ethyl)-1,3-dihydro-3,3-dimethyl-2H- indol-2-ylidene)-1,3,5-heptatrienyl]-5-{N-[2- (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10- heptadecafluorodecyloxy)-ethyl]- aminocarbonyl}-3,3-dimethyl-1-(4-sulfobutyl)- 3H-indolium, internal salt, sodium salt 13 1112.9 2-[5-(1-ethyl)-1,3-dihydro-3,3-dimethyl-2H- indol-2-ylidene)-1,3-pentatrienyl]-5-{N-[2- (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10- heptadecafluorodecyloxy)ethyl]-N-(2,3- dihydroxypropyl)aminocarbonyl}-3,3-dimethyl- 1-(4-sulfobutyl)-3H-indolium, internal salt, sodium salt 14 1138.9 2-[5-(1-ethyl)-1,3-dihydro-3,3-dimethyl-2H- indol-2-ylidene)-1,3 5-heptatrienyl]-5-{N-[2- (3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10- heptadecafluorodecyloxy)-ethyl]-N-(2,3- dihydroxypropyl)aminocarbonyl}-3,3-dimethyl- 1-(4-sulfobutyl)-3H-indolium, internal salt, sodium salt - A solution of 0.5 mmol of dye 3 or 4 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.29 g (0.55 mmol) of 5 and 0.6 mmol of triethylamine in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 2 hours at room temperature. After 100 ml of hexane is added, the precipitated solid is filtered off and purified chromatographically on RP-silica gel LiChroprep® RP-8 (Merck), 40-63μ (eluant: water/MeOH, step gradient of 30% to 90% MeOH); yields: 0.25 g (48%) of 11, 0.35 g (66%) of 12.
- A solution of 0.5 mmol of dye 1 or 2 and 0.1 g (1.0 mmol) of triethylamine in 20 ml of dimethylformamide is mixed at 0° C. with 0.5 mmol of TBTU in 10 ml of dimethylformamide and stirred for 15 minutes at 0° C. Then, a solution of 0.37 g (0.65 mmol) of 6 in 5 ml of dimethylformamide is added in drops, and the reaction mixture is stirred for 18 hours at room temperature. After 100 ml of hexane is added, the precipitated solid is filtered off and purified chromatographically on RP-silica gel LiChroprep® RP-8 (Merck), 40-63μ (eluant: water/MeOH, step gradient of 20% to 80% MeOH); yields: 0.39 g (70%) of 13, 0.41 g (72%) of 14.
-
-
-
- 5-Carboxy-X-rhodamine-perfluoroalkylamide
- 118 mg (100 μmol) of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see WO 97/26017, Example 33) is dissolved together with 1 μmol, 2 μmol, 5 μmol or 10 μmol of 7 to 14 in 50 ml of water for 20 minutes in an ultrasound bath. Then, a dialysis to separate free dyes is performed (Amicon cell, cut-off 10,000, dialysis volumes 5×100 ml). The product solution is set at a volume of 5 ml (20 mmol/l) of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane) with water.
- In addition to 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, the following Gd-complex perfluoroalkyl derivatives were used for the production of the galenical formulations:
- Gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-oxa-10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,17-heptadecafluoro-heptadecyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see DE 196 03 033, Example 2)
- Gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7-(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (for production, see DE 196 03 033, Example 1)
- 1,4,7-Tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex
- Production
- 10 g (15.88 mmol) of the gadolinium complex of 10-[1-(carboxymethylcarboamoyl)-ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid and 1.35 g (31.76 mmol) of lithium chloride and 3.66 g (31.76 mmol) of N-hydroxysuccinimide are dissolved at 60° C. in 100 ml of dimethyl sulfoxide. It is cooled to 15° C., and 3.51 (17 mmol) of N,N′-dicyclohexylcarbodiimide is added and stirred for 5 hours at 15° C. To separate the urea, the solution is filtered. 8.63 g (15.88 mmol) of 1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecylamine, hydrochloride and 5.06 g (50 mmol) of triethylamine are added to the filtrate and stirred for 12 hours at room temperature. The solution is poured into 1,500 ml of diethyl ether/100 ml of acetone and stirred for 30 minutes. The precipitated solid is filtered off and chromatographed on silica gel RP-18 (mobile solvent: gradient that consists of tetrahydrofuran/acetonitrile/water).
- Yield: 13.86 g (78% of theory) of a colorless, amorphous powder
- Water content: 9.3%
- Elementary analysis (relative to anhydrous substance):
Cld: C 33.28 H 3.42 N 7.51 F 28.87 Gd 14.05 Fnd: C 33.12 H 3.61 N 7.37 F 28.69 Gd 13.89 - 1,4,7-Tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(2,3-dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex
- Production
- a) 2H,2H,4H,4H,5H,5H-3-Oxa)-perfluorotridecanoic acid-N-(2,3-dihydroxypropyl)-amide
- 8.90 g (70 mmol) of oxalyl chloride is added to 30 g (57.45 mmol) of 2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecanoic acid in 300 ml of dichloromethane, and it is stirred for 12 hours at room temperature. It is evaporated to the dry state in a vacuum. The residue is dissolved in 100 ml of dichloromethane and added in drops at 0° C. to a solution of 5.47 g (60 mmol) of 2,3-dihydroxypropylamine and 6.07 g (60 mmol) of triethylamine, dissolved in 200 ml of dichloromethane. It is stirred for 3 hours at 0° C., then for 6 hours at room temperature. 300 ml of 5% aqueous hydrochloric acid is added, and it is thoroughly stirred for 15 minutes.- The organic phase is separated, dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/ethanol=15:1).
- Yield: 29.70 g (87% of theory) of a colorless solid
- Elementary analysis:
Cld: C 30.32 H 2.20 N 2.36 F 54.35 Fnd: C 30.12 H 2.41 N 2.18 F 54.15 - b) N-(2,3-Dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amine
- 30 g (48.8 mmol) of the title compound of Example a is dissolved in 300 ml of tetrahydrofuran, and 50 ml of 10 M borane dimethyl sulfide (in tetrahydrofuran) is added. It is refluxed for 16 hours. It is cooled to 0° C., and 300 ml of methanol is added in drops, then it is evaporated to the dry state in a vacuum. The residue is taken up in a mixture of 300 ml of ethanol/50 ml of 10% aqueous hydrochloric acid and stirred for 8 hours at 60° C. It is evaporated to the dry state in a vacuum, the residue is taken up in 300 ml of 5% aqueous sodium hydroxide solution and extracted three times with 300 ml of dichloromethane each. The organic phases are dried on magnesium sulfate, evaporated to the dry state in a vacuum, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/methanol=15:1).
- Yield: 24.07 g (85% of theory) of a colorless solid
- Elementary-analysis:
Cld: C 31.05 H 2.61 N 2.41 F 55.66 Fnd: C 31.91 H 2.78 N 2.33 F 55.47 - c) 1,4,7-Tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(2,3-dihydroxypropyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex
- 10 g (15.88 mmol) of the gadolinium complex of 10-[1-(carboxymethylcarboamoyl)-ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid and 1.35 g (31.76 mmol) of lithium chloride are dissolved at 60° C. in 100 ml of dimethyl sulfoxide. It is cooled to 15° C., and 9.21 (15.88 mmol) of the title compound of Example b is added. It is stirred for 10 minutes, and then 7.42 g (30 mmol) of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline is added. It is stirred for 12 hours at room temperature. The solution is poured into a mixture of 200 ml of acetone/1300 ml of diethyl ether and stirred for 2 hours at room temperature. The deposited precipitate is filtered off, dissolved in a mixture that consists of a little ethanol/water and chromatographed on silica gel RP-18 (mobile solvent: gradient that consists of tetrahydrofuran/acetonitrile/water).
- Yield: 16.09 g (85% of theory) of a colorless, amorphous powder
- Water content: 6.3%
- Elementary analysis (relative to anhydrous substance):
Cld: C 34.26 H 3.64 N 7.05 F 27.10 Gd 13.19 Fnd: C 34.12 H 3.83 N 6.91 F 26.88 Gd 12.93 - 1,4,7-Tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(5-hydroxy-3-oxa-pentyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex
- Production
- a) 2H,2H,4H,4H,5H,5H-3-Oxa-perfluorotridecanoic acid-N-(5-hydroxy-3-oxa-pentyl)-amide
- 8.90 g (70 mmol) of oxalyl chloride is added to 30 g (57.45 mmol) of 2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecanoic acid in 300 ml of dichloromethane and stirred for 12 hours at room temperature. It is evaporated to the dry state in a vacuum. The residue is dissolved in 100 ml of dichloromethane and added in drops at 0° C. to a solution of 6.25 g (60 mmol) of 5-hydroxy-3-oxa-pentylamine and 6.07 g (60 mmol) of triethylamine, dissolved in 200 ml of dichloromethane. It is stirred for 3 hours at 0° C., then for 6 hours at room temperature. 300 ml of 5% aqueous hydrochloric acid is added, and it is thoroughly stirred for 15 minutes. The organic phase is separated, dried on magnesium sulfate and evaporated to the dry state in a vacuum. The residue is chromatographed on silica gel (mobile solvent: dichloromethane/acetone=15:1).
- Yield: 32.20 g (92% of theory) of a colorless solid
- Elementary analysis:
Cld: C 31.54 H 2.65 N 2.30 F 53.01 Fnd: C 31.61 H 2.84 N 2.14 F 52.85 - b) N-(5-Hydroxy-3-oxa-pentyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amine
- 30 g (49.24 mmol) of the title compound of Example a is dissolved in 300 ml of tetrahydrofuran, and 31 ml of 10 M borane dimethyl sulfide (in tetrahydrofuran) is added. It is refluxed for 16 hours. It is cooled to 0° C., and 200 ml of methanol is added in drops, then it is evaporated to the dry state in a vacuum. The residue is taken up in a mixture of 300 ml of ethanol/50 ml of 10% aqueous hydrochloric acid and stirred for 10 hours at 50° C. It is evaporated to the dry state in a vacuum, the residue is taken up in 300 ml of 5% aqueous sodium hydroxide solution and extracted three times with 300 ml of dichloromethane each. The organic phases are dried on magnesium sulfate, evaporated to the dry state in a vacuum, and the residue is chromatographed on silica gel (mobile solvent: dichloromethane/2-propanol=20:1).
- Yield: 26.09 g (89% of theory) of a colorless solid
- Elementary analysis:
Cld: C 32.28 H 3.05 N 2.35 F 54.25 Fnd: C 32.12 H 3.21 N 2.18 F 54.09 - c) 1,4,7-Tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(5-hydroxy-3-oxa-pentyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetrazacyclododecane, gadolinium complex
- 10 g (15.88 mmol) of the gadolinium complex of 10-[1-(carboxymethylcarboamoyl)-ethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid and 1.35 g (31.76 mmol) of lithium chloride are dissolved at 60° C. in 100 ml of dimethyl sulfoxide. It is cooled to 15° C., and 9.45 (15.88 mmol) of the title compound of Example b is added. It is stirred for 10 minutes, and then 7.42 g (30 mmol) of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline is added. It is stirred for 12 hours at room temperature. The solution is poured into a mixture of 200 ml of acetone/1300 ml of diethyl ether and stirred for 2 hours at room temperature. The deposited precipitation is filtered off, dissolved in a mixture that consists of a little ethanol/water and chromatographed on silica gel RP-18 (mobile solvent: gradient that consists of tetrahydrofuran/acetonitrile/water).
- Yield: 16.10 g (84% of theory) of a colorless, amorphous powder
- Water content: 5.7%
- Elementary analysis (relative to anhydrous substance):
Cld: C 34.83 H 3.84 N 6.96 F 26.76 Cd 13.03 Fnd: C 34.65 H 3.96 N 6.84 F 26.62 Cd 12.91 - a) 1,2,3,4,6-Penta-O-acetyl-α,β-D-mannopyranose
- Analogously, as described in the literature [M. L. Wolfrom and A. Thompson in Methods in Carbohydrate Chemistry (R. L. Whistler, M. L. Wolfrom and J. N. BeMiller, Eds.), Academic Press, New York, Vol. II, 53, pp. 211-215, (1963)], the reaction of 150 g (832.5 mmol) of α,β-D-mannopyranose with a mixture that consists of 1,500 ml of absolute pyridine and 1,500 ml of acetic acid anhydride provides, after working-up, 315 g (96.7%) of the above-mentioned title compound as a crude product in the form of a viscous and colorless oil. By1H-NMR-spectroscopic study of the title compound that is thus obtained, the α to β-ratio of both anomers was found to be 4:1. A separation of the α,β-anomers of the above-mentioned title compound can be dispensed with for performing the reaction steps below.
- Elementary analysis:
Cld: C 49.21 H 5.68 Fnd: C 49.12 H 5.78 - b) 6-[1-O-α-(2,3,4,6-Tetra-O-acetyl-D-mannopyranosyl)-hexanoic acid ethyl easter]
- Analogously, as described in the literature for the synthesis of aryl glycopyranosides [J. Conchie and G. A. Levvy in Methods in Carbohydrate Chemistry (R. L. Whistler, M. L. Wolfrom and J. N. BeMiller, Eds.), Academic Press, New York, Vol. II, 90, pp. 345-347, (1963)], the reaction of 156.2 g (400 mmol) of the title compound of Example Aa) as an α,β-anomer mixture with 67 ml (400 mmol) of 6-hydroxy-hexanoic acid ethyl ester and 60.8 ml (520 mmol) of tin(IV) chloride in a total of 600 ml of 1,2-dichloroethane results in the formation of 100.05 g (51% of theory) of the above-mentioned title compound as a colorless and viscous oil after column-chromatographic purification (eluant: hexane/ethyl acetate 2:1).1H-NMR-spectroscopic study of the title compound that is thus obtained showed that the above-mentioned title compound is only the pure α-anomer.
- Elementary analysis:
Cld: C 52.94 H 6.77 Fnd: C 52.80 H 6.78 - c) 6-[1-O-α-(2,3,4,6-Tetra-O-benzyl-D-mannopyranosyl)-hexanoic acid
- A stirred suspension of 141.0 g (289 mmol) of the title compound of Example Ab) in 200 ml of dioxane is mixed at room temperature and with simultaneous vigorous stirring in portions with a total of 238.5 g (4.26 mol) of finely powdered potassium hydroxide powder. To increase the stirrability, the reaction mixture is mixed with another 200 ml of dioxane, and the suspension that is thus obtained is subsequently heated to boiling and mixed drop by drop at this temperature with a total of 372 ml (3.128 mol) of benzyl bromide over a period of two hours. After a reaction time of 4 hours at 110° C. followed by 12 hours at room temperature, the reaction mixture is slowly poured into a total of 2.5 liters of ice water for the purpose of working-up, and the water phase is subsequently completely extracted with diethyl ether. After the ether phase that is thus obtained is washed and the same is subsequently dried on sodium sulfate, salt is suctioned out, and the diethyl ether is removed in a vacuum. Excess benzyl bromide is then quantitatively distilled off from the reaction mixture in an oil pump vacuum at an oil bath temperature of 180° C. The resinous-oily residue that is thus obtained is purified on silica gel with use of ethyl acetate/hexane (1:10) as an eluant.
- Yield: 172.2 g (91.0% of theory) of the above-mentioned title compound in the form of a colorless and extremely viscous oil
- Elementary analysis:
Cld: C 75.68 H 7.16 Fnd: C 75.79 H 7.04 - d) 6-[1-O-α-(2,3,4,6-Tetra-O-benzyl-D-mannopyranosyl)-hexanoic acid-N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide
- 100 g (134 mmol) of the acid that is described in Example Ac) and 13.5 g (134 mmol) of triethylamine are dissolved in 1,200 ml of dry tetrahydrofuran. After cooling to −15° C., a solution of 18.45 g (135 mmol) of isobutyl chloroformate in 200 ml of dry tetrahydrofuran is slowly added in drops while being stirred, whereby the internal temperature does not exceed −10° C. After a reaction time of 15 minutes at −15° C., a solution of 165.5 g (134 mmol) of 1-amino-1H,1H,2H,2H-perfluorodecane and 13.5 g (134 mmol) of triethylamine in 250 ml of dry tetrahydrofuran are added in drops at −20° C. After a reaction time of one hour at −15° C. and two hours at room temperature, the reaction solution is evaporated to the dry state in a vacuum. The remaining residue is taken up in 300 ml of ethyl acetate and washed twice with 400 ml of saturated sodium bicarbonate solution each and once with 500 ml of water. After the organic phase is dried on sodium sulfate, salt is suctioned out, and the ethyl acetate is removed in a vacuum. The remaining oily residue is purified on silica gel with use of dichloromethane/hexane/2-propanol (10:5:1) as an eluant.
- Yield: 143.8 g (86.9% of theory)
- Elementary analysis:
Cld: C 57.38 H 4.98 N 1.13 F 26.15 Fnd: C 57.30 H 5.44 N 1.01 F 26.25 - e) 6-[1-O-α-D-Mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide
- 40.0 g (32.38 mmol) of the title compound of Example Ad) is dissolved in 750 ml of 2-propanol and mixed with 2.0 g of palladium catalyst (10% Pd/C). The reaction solution is hydrogenated for 12 hours at 22° C. and 1 atmosphere of hydrogen pressure.
- Then, catalyst is filtered off, and the filtrate is evaporated to the dry state. The remaining residue is taken up in 300 ml of dimethyl sulfoxide, and 21.52 g (88.0% of theory) of the above-mentioned title compound is obtained as a colorless and crystalline powder with the decomposition melting point of 88.5° C. from the product solution that is thus obtained by mixing with a total of 1000 ml of diethyl ether after the precipitated solution is suctioned off.
- Elementary analysis:
Cld: C 36.01 H 5.92 N 1.75 F 40.34 Fnd: C 36.07 H 6.08 N 1.76 F 40.66 - 100 μmol of 6-[1-O-α-D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide is dissolved in 0.5 ml of ethanol, then mixed with 50 ml of water, and 1, 2, 5 and 10 mol % of dyes 7 to 14 are added in solid form. After 1 hour of treatment in an ultrasound bath, dialysis is carried out as described in Example 13.
- In addition to 6-[1-O-α-D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide, the following monosaccharide-perfluoroalkyl derivatives I-III can be used for the production of galenical formulations:
- a) 1-O-α-D-[(1-Perfluorooctylsulfonylpiperazine-4-carbonyl)-pentyl-5]-2,3,4,6-tetra-O-benzyl-mannopyranose
- 74.59 g (100 mmol) of the acid that is described in Example Ac) and 10.11 g (100 mmol) of triethylamine are dissolved in 800 ml of a mixture of tetrahydrofuran/acetonitrile (mixing ratio 7:3). Then, it is mixed drop by drop at room temperature with 500 ml of a tetrahydrofuran solution of 58.0 g (102.0 mmol) of 1-perfluorooctyl-sulfonylpiperazine; 10,11 g (100 mmol) of triethylamine and 16.84 g (110 mmol) of 1-hydroxybenzotriazole. The reaction solution that is thus obtained is mixed at −5° C. with a solution of 22.7 g (110 mmol) of dicyclohexylcarbodiimide, dissolved in 100 ml of tetrahydrofuran, and then stirred at −5° C. for two more hours. After the reaction solution has thawed, it is stirred at room temperature for another 12 hours, precipitated dicyclohexylurea is filtered out, and the filtrate that is obtained is evaporated to the dry state in a vacuum. The remaining residue is taken up in 600 ml of ethyl acetate and washed twice with 300 ml of saturated sodium bicarbonate solution each as well as twice with 300 ml of water each.
- After the organic phase is dried on sodium sulfate, salt is suctioned out, and the ethyl acetate is removed in a vacuum. The remaining oily residue is purified on silica gel with use of dichloromethane/acetone/2-propanol (16:2:1) as an eluant.
- Yield: 113.01 g (79.8% of theory) of a colorless and viscous oil
- Elementary analysis:
Cld: C 58.52 H 4.27 N 1.98 S 2.26 F 22.80 Fnd: C 58.42 H 4.41 N 1.80 S 2.28 F 23.02 - b) 1-O-α-D-[(1-Perfluorooctylsulfonyl-piperazine-4-carbonyl)-pentyl-5]-mannopyranose
- 50 g (35.30 mmol) of the title compound of Example Ia) is dissolved in a mixture that consists of 500 ml of 2-propanol and 50 ml of water, and 2 g of palladium catalyst (10% Pd on activated carbon) is added. It is hydrogenated for 12 hours at room temperature. Catalyst is filtered out, and the filtrate is evaporated to the dry state in a vacuum. The residue is dissolved in 200 ml of methanol, and the reaction product is precipitated by mixing with a total of 800 ml of diethyl ether. After the solid that is thus obtained is suctioned off, the latter is dried in a vacuum at 50° C.
- Yield: 29.51 g (99% of theory) of an amorphous solid
- Elementary analysis:
Cld: C 34.13 H 3.46 N 3.32 S 3.80 F 38.23 Fnd: C 34.28 H 3.81 N 3.25 S 3.80 F 38.01 - a) 2-Acetamido-2-deoxy-1,3,4,6-(tetra-O-benzyl)-α,β-D-glucopyranose
- A total of 24.0 g (108.5 mmol) of 2-acetamido-2-deoxy-α,β-D-glucopyranose, dissolved in 500 ml of absolute dimethyl sulfoxide, is added drop by drop at room temperature to a stirred suspension of 20.16 g (700 mmol/80% in mineral oil) of sodium hydride in 150 ml of dimethyl sulfoxide. Then, it is allowed to stir for 120 more minutes at room temperature, and then 159.5 g (1.26 mol) of benzyl chloride is added in drops. The reaction solution that is thus obtained is subsequently stirred for another 12 hours at room temperature. For working-up, the reaction solution is slowly poured into 1.5 liters of ice water and then exhaustively extracted with diethyl ether. The combined diethyl ether phases are subsequently washed twice with 600 ml of saturated sodium bicarbonate solution each and twice with 800 ml of water each. After the organic phase is dried on sodium sulfate, salt is suctioned out, and the solvent is removed in a vacuum. The remaining oily residue is purified on silica gel with use of ethyl acetate/hexane (1:5) as an eluant.
- Yield: 48.68 g (73.6% of theory) of the above-mentioned title compound in the form of a viscous and colorless oil
- Elementary analysis:
Cld: C 70.92 H 6.45 N 6.89 Fnd: C 71.43 H 6.44 N 7.02 - b) 1-O-Benzyl-3,4,6-tri-O-benzyl-2-amino-2-deoxy-α,β-D-glucopyranose
- 30.0 g (49.2 mmol) of the title compound of Example IIa) is suspended in a mixture of 750 ml of methanol and 215 ml of water and mixed drop by drop at room temperature with a total of 440 ml (49.2 mmol) of a 0.112 molar aqueous perchloric acid solution. After the addition is completed, the reaction solution is stirred for 10 more minutes at room temperature, and the now homogenous reaction solution that is thus obtained is subsequently evaporated to the dry state in a vacuum. By mixing the remaining oily residue with a mixture that consists of equal parts of hexane and dichloromethane, the latter is crystallized. The crystalline reaction product is suctioned off, washed with hexane and dried in a vacuum at room temperature.
- Yield: 27.08 g (86% of theory) of the above-mentioned title compound in the form of its perchlorate, which is present as a colorless, crystalline compound.
- Melting point: 180.5-181.5° C.
- Elementary analysis:
Cld: C 63.68 H 5.98 N 2.19 Cl 5.54 Fnd: C 63.43 H 6.04 N 2.02 Cl 5.71 - c) 1,3,4,6-Tetra-O-benzyl-2-deoxy-2-[acetyl-(2-amino-N-ethyl-N-perfluorooctylsulfonyl)-amino]-1-α,β-D-mannopyranose
- 20.8 g (35.6 mmol) of the 2-[N-ethyl-N-perfluorooctylsulfonyl]-aminoacetic acid and 3.60 g (35.6 mmol) of triethylamine are dissolved in 350 ml of dry tetrahydrofuran. After the reaction solution is cooled to −15° C. to −20° C., a solution of 4.92 g (35.6 mmol) of isobutyl chloroformate in 75 ml of dry tetrahydrofuran is slowly added in drops at this temperature while being stirred, whereby the dropwise addition rate is to be selected so that an internal temperature of −10° C. is not exceeded. After a reaction time of 15 minutes at −15° C., a solution of 22.78 g (35.6 mmol) of the perchlorate (title compound of Example IIb) and 3.60 g (35.6 mmol) of triethylamine, in 100 ml of dry tetrahydrofuran, is then slowly added in drops at −20° C. After a reaction time of one hour at −15° C. and two hours at room temperature, the reaction solution is evaporated to the dry state in a vacuum. The remaining residue is taken up in 250 ml of ethyl acetate and washed twice with 100 ml of saturated sodium bicarbonate solution each and once with 200 ml of water. After the organic phase is dried on sodium sulfate, salt is suctioned out, and the ethyl acetate is removed in a vacuum. The remaining oily residue is purified on silica gel with use of ethyl acetate/hexane (1:5) as an eluant.
- Yield: 33.3 g (84.6% of theory) of the above-mentioned title compound as a colorless and strongly viscous oil
- Elementary analysis:
Cld: C 49.92 H 3.92 N 2.53 F 29.18 S 2.90 Fnd: C 49.99 H 4.11 N 2.69 F 29.22 S 3.01 - d) 2-Deoxy-2-[acetyl-(2-amino-N-ethyl-N-perfluorooctylsulfonyl)-amino]-1-α,β-D-mannopyranose
- 20.0 g (18.06 mmol) of the title compound of Example IIc) is dissolved in 250 ml of 2-propanol and mixed with 1.5 g of palladium catalyst (10% Pd/C). The reaction solution is hydrogenated for 12 hours at 22° C. and 1 atmosphere of hydrogen pressure. Then, catalyst is filtered out, and the filtrate is evaporated to the dry state. The remaining residue is taken up in 300 ml of dimethyl sulfoxide, and 12.65 g (93.8% of theory) of the above-mentioned title compound is obtained as a colorless and crystalline powder from the product solution that is thus obtained by mixing with 750 ml of a mixture that consists of equal parts of dimethyl ether and ethyl acetate after the precipitated solid is suctioned off. The above-mentioned title compound is present as an α/β-anomer mixtures, whereby the ratio relative to the two possible anomers was determined at about 1:1.2 by1H-NMR-spectroscopic studies. Accordingly, the title compound is an almost approximately evenly divided α/β-anomer mixture.
- Melting point: 132.5-133° C.
- Elementary analysis:
Cld: C 28.97 H 2.57 N 3.75 F 43.27 S 4.30 Fnd: C 29.09 H 2.56 N 3.84 F 43.36 S 4.42 - a) 1,2,3,4,6-Penta-O-acetyl-α-D-glucopyranose
- Analogously, as described in the synthesis of title compound Aa), the reaction of 100 g (555.0 mmol) of α-D-glucopyranose with a mixture of 1000 ml of absolute pyridine and 1000 ml of acetic acid anhydride after working-up and recrystallization from 95% aqueous ethanol yields 190.6 g (88.0%) of the above-mentioned title compound as a colorless and crystalline compound. By1H-NMR-spectroscopic study of the title compound that is thus obtained, it was possible to determine the α to β-ratio of two possible anomers with ≧98:2. Accordingly, the title compound is the exclusively α-configured anomer.
- Melting point: 110.5° C.
- Elementary analysis:
Cld: C 49.21 H 5.68 Fnd: C 49.24 H 5.68 - b) 5-(Ethoxycarbonyl)pentyl-2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside
- Analogously, as described in the synthesis of the title compound of Example Ab), the reaction of 130.0 g (332.8 mmol) of the title compound of Example IIIa) with 55.8 ml (332.8 mmol) of 6-hydroxy-hexanoic acid ethyl ester and 50.6 ml (520 mmol) of tin(IV) chloride in 500 ml of 1,2-dichloroethane after column-chromatographic working-up (eluant: hexane/ethyl acetate 2:1) yields 101.85 g (62.4% of theory) of the above-mentioned title compound as a colorless and viscous oil. After1H-NMR-spectroscopic study of the title compound, the presence of the β-configuration at the anomeric center was definitively established based on the size of the coupling constant of J1,2=8.8 Hz; moreover, said configuration represents the sole existing configuration at the anomeric center. It was thus possible to depict the above-mentioned title compound only in the form of the β-configured anomer.
- Elementary analysis:
Cld: C 52.94 H 6.77 Fnd: C 52.77 H 6.70 - c) 5-(Carboxyypentyl-2,3,4,6-tetra-O-benzyl-α-D-mannopyranoside
- A stirred suspension of 100.0 g (204.96 mmol) of the title compound of Example IIIb) in 150 ml of dioxane is mixed at room temperature and with simultaneous, vigorous stirring in portions with a total of 169.14 g (3.02 mol) of finely powdered potassium hydroxide powder. To increase the stirrability, the reaction mixture is mixed with another 150 ml of dioxane, and the suspension that is thus obtained is subsequently heated to boiling and mixed drop by drop at this temperature with a total of 264 ml (2.218 mol) of benzyl bromide over a period of two hours. After a reaction time of 4 hours at 110° C. followed by 12 hours at room temperature, the reaction mixture is slowly poured into a total of 2.0 liters of ice water for the purpose of working-up, and the water phase is subsequently completely extracted with diethyl ether. After the ether phase that is thus obtained is washed and said phase is subsequently dried on sodium sulfate, salt is suctioned out, and the diethyl ether is removed in a vacuum. Excess benzyl bromide is then quantitatively distilled off from the reaction mixture in an oil pump vacuum at an oil bath temperature of 180° C. The remaining oily residue that is thus obtained is purified on silica gel with use of ethyl acetate/hexane (1:10) as an eluant.
- Yield: 128.8 g (84.3% of theory) of the above-mentioned title compound in the form of a colorless and extremely viscous oil
- Elementary analysis:
Cld: C 75.68 H 7.16 Fnd: C 75.66 H 7.23 - d) 2,3,4,6-Tetra-O-benzyl-1-O-β-D-[6-hexanoic acid-N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide]-glucopyranose
- 68.5 g (91.79 mmol) of the acid that is described in Example IIIc) and 9.25 g (91.79 mmol) of triethylamine are dissolved in 825 ml of dry tetrahydrofuran. After the reaction solution is cooled to −15° C. to −20° C., a solution of 12.64 g (92.5 mmol) of isobutyl chloroformate in 150 ml of dry tetrahydrofuran is slowly added in drops at this temperature while being stirred, whereby the dropwise addition rate is to be selected such that an internal temperature of −10° C. is not exceeded. After a reaction time of 15 minutes at −15° C., a solution of 46.40 g (91.79 mmol) of 1H,1H,2H,2H-heptadecafluoro-1-(2-aminoethyoxy)-decane and 9.25 g (91.79 mmol) of triethylamine is then slowly added in drops at −20° C. as a solution in 200 ml of dry tetrahydrofuran. After a reaction time of one hour at −15° C., and two hours at room temperature, the reaction solution is evaporated to the dry state in a vacuum. The remaining residue is taken up in 250 ml of ethyl acetate and washed twice with 300 ml of saturated sodium bicarbonate solution each and once with 400 ml of water. After the organic phase is dried on sodium sulfate, salt is suctioned out, and the ethyl acetate is removed in a vacuum. The remaining oily residue is purified on silica gel with use of dichloromethane/hexane/2-propanol (10:5:1) as an eluant.
- Yield: 104.7 g (92.4% of theory) of the above-mentioned title compound as a colorless and strongly viscous oil.
- Elementary analysis:
Cld: C 57.38 H 4.98 N 1.13 F 26.15 Fnd: C 57.27 H 5.09 N 1.11 F 26.08 - e) 1-O-β-D-[6-Hexanoic acid-N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide]-glucopyranose
- 40.0 g (32.38 mmol) of the title compound of Example IIId) is dissolved in 750 ml of 2-propanol and mixed with 2.0 g of palladium catalyst (10% Pd/C). The reaction solution is hydrogenated for 12 hours at 22° C. and 1 atmosphere of hydrogen pressure. Then, catalyst is filtered out, and the filtrate is evaporated to the dry state. The remaining residue is taken up in 300 ml of dimethyl sulfoxide and 22.05 g (90.2% of theory) of the title compound is obtained as a colorless and crystalline powder with a decomposition melting point of 122-124° C. from the product solution that is thus obtained by mixing with a total of 1000 ml of diethyl ether and subsequent suctioning-off of the precipitated solid.
- Elementary analysis:
Cld: C 36.01 H 5.92 N 1.75 F 40.34 Fnd: C 36.07 H 6.08 N 1.76 F 40.66 - The production was performed analogously to the general instructions of Example 14 with use of various proportions of 6-[1-O-α-D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide and 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, and of 5 mol % of dyes 7 to 14 in each case. In this case, 6-[1-O-α-D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide was dissolved in ethanol, mixed with a solution of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane in water, and the mixture was treated in an ultrasound bath after dye was added, and the procedure was as in Example 13.
- The determination of the absorption maxima and extinction coefficients was carried out with a Lambda 2-spectrometer (Perkin-Elmer Company). The fluorescence properties were determined on a SPEX-fluorolog (Instruments S. A. Company, Photomultiplier Hamamatsu PM928, excitation 350W xenon lamp). The determination of the fluorescence quantum yield was carried out relative to indocyanine green (O=13% in DMSO) by excitation at 585 nm (dyes with p=2) or 685 nm (dyes with p=3), in each case of solutions of concentration 2 μM in dye, and correction with the spectral sensitivity of lamp and detector.
- Absorption and fluorescence properties of formulations with 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-traazacyclododecane depending on the dye proportion in the example of dyes 7 and 8
Extinction coefficient Fluorescence Mol % of Absorption (L mol−1 Fluorescence quantum Dye dye max. (nm) cm−1) max. (nm) yield 7 1 652 132,000 681 0.17 7 2 651 120,200 683 0.18 7 5 651 123,700 685 0.12 7 10 649 110,900 685 0.04 8 1 755 150,500 784 0.23 8 2 755 148,800 785 0.23 8 5 753 120,800 788 0.14 8 10 751 108,500 790 0.03 - Absorption and fluorescence properties of the galenical formulation with 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane and dyes 7-14 in a proportion of 5 mol %
Extinction coefficient Fluorescence Mol % of Absorption (L mol−1 Fluorescence quantum Dye dye max. (nm) cm−1) max. (nm) yield 7 5 651 123,700 685 0.12 8 5 753 120,800 788 0.14 9 5 653 145,000 683 0.14 10 5 754 118,800 788 0.13 11 5 650 150,700 684 0.16 12 5 753 124,100 789 0.09 13 5 653 139,400 682 0.12 14 5 754 120,900 789 0.11 - Aborption and fluorescence properties of the galenical formulations with 6-[1-O-α-D-mannopyranosyl)-hexanoic acid N-(3-oxo-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide, 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane and dye 8 in a proportion of 5 mol %
Extinction Mol % Mol % Mol % Absorption coefficient Flourescence Flourescence of of Gd of mono- maximum (L mol−1 maximum quantum Dye Dye complex saccharide (nm) cm−1) (nm) yield 8 5 0 95 760 90500 800 0.16 8 5 10 85 760 102700 800 0.11 8 5 30 65 760 107900 800 0.14 8 5 50 45 756 108700 798 0.26 8 5 70 25 756 111100 794 0.18 8 5 90 5 755 112500 793 0.13 - The galenical formulations that are produced according to the instructions of Examples 13 to 15 are freeze-dried according to common procedures. The blue-colored lyophilizates are stored for 5 days at room temperature, then resuspended by shaking in 5-10 ml of water and subjected to dialysis as described above. The dye content after dialysis was determined photometrically and in all cases amounted to 96-99% relative to the content before freeze-drying and resuspension.
- The imaging properties of the formulations according to the invention were studied in vivo in guinea pigs. In this respect, a formulation was administered interstitially/intracutaneously, and the concentration in regional lymph nodes was observed in a period of 0 to 120 minutes. The fluorescence of the substances was stimulated by irradiation of the animals with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser. The fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 1 shows near-infrared fluorescence images of a guinea pig after interstitial/intracutaneous administration of formulations with 5 mol % of dye 8/95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane. 0.1 ml of a stock solution with 1 mmol/L of 8 was injected into a skin fold between the toes of the right rear extremity, and the final concentration was 0.3 μmol/kg of 8.
- A. Abdominal view, 120 minutes after administration, the right rear foot of the animal was covered during imaging, since the injection site had a strong fluorescence signal.
- B. Right lateral view, 117 minutes after administration, the right rear leg of the animal was covered in the imaging, since the injection site had a strong fluorescence signal.
- After the interstitial near-infrared lymphography was completed, the regional lymph nodes were prepared in the area of the administration site. It was observed that these lymph nodes have a green coloring because of the accumulation of the substance according to the invention. This coloring can be used for the intraoperative diagnosis for the identification of the draining lymph nodes of a certain tissue area and for differentiating the lymph nodes from the surrounding tissue.
- FIG. 2 shows two inguinal lymph nodes of guinea pigs after interstitial/intracutaneous administration of a formulation with 5 mol % of dye 8/95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (A, B) and a lymph node of an untreated guinea pig ex vivo (C). A formulation with 5 mol % of dye 8 resulted in a clearly visible green-coloring of the lymph nodes after interstitial administration.
- The localization of the formulations according to the invention in lymph nodes was studied by fluorescence microscopy on frozen sections of the lymph nodes. In this respect, the lymph nodes were prepared after the lymphography and deep-frozen at −80° C. Sections with a 5 μm thickness were produced on a freezing microtome. The evaluation was carried out on a Zeiss Axiovert 135-fluorescence microscope, which was equipped with a Cy 7-(excitation filter HQ710/70 nm, emission filter 810/90 nm, beam splitter 750 nm LP). From all the preparations, white light and fluorescence images were recorded with a CCD camera (Princeton Instruments RTE/CCD-576) and stored digitally.
- FIG. 3 shows a bright-field (1a) and a near-infrared-fluorescence image (1b) of a frozen section of a popliteal guinea pig lymph node four hours after interstitial administration of a formulation with 5 mol % of dye 8/95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane. Images of a cryosection from a popliteal lymph node of an untreated guinea pig in bright field (2a) and in near-infrared-fluorescence (2b) are shown for comparison. Lymph nodes from guinea pigs that had received an interstitial/intracutaneous injection of the formulation showed a pronounced fluorescence in the near-infrared wavelength range, while the lymph nodes of untreated animals have no fluorescence.
- Image parameters:
- Bright field: Lens 2.5×. Exposure 0.02 seconds, no accumulation. Tube enlargement 0.6.
- NTR: Lens 2.5×. Exposure 1 second, accumulation 5×, tube enlargement 0.6, Cy7-set of filters.
- From the substance, 0.2 ml of a solution that contained 0.5 mmol/L of dye 8 and 9.5 mmol/L of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulflonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, was administered intravenously in a caudal vein of the rat. Five hours after administration, the lymph nodes were prepared and a fluorescence image was recorded. The fluorescence of the substances was stimulated by irradiation of the lymph nodes with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser. The fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 4 shows a fluorescence image of lymph nodes 5 hours after intravenous administration of a formulation with 5 mol % of dye 8 and 95 mol % of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane. Shown are the axillary (a, a′), inguinal (b, b′) and popliteal (c, c′) lymph nodes of the animal. All lymph nodes showed a clear fluorescence signal.
- FIG. 5 shows a fluorescence image of an abdominally-opened rat five hours after interstitial administration of a formulation with 5 mol % of dye 8 and 95 mol % of mannose in a skin fold between the toes of the right rear extremity. The axillary and the inguinal lymph nodes and a connected lymph tract are visualized based on a fluorescence signal.
- From the substance, 0.1 ml of a solution that contained 1 mmol/L of dye 8 and 19 mmol/L of 6-[1-O-α-D-mannopyranosyl]-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide was administered interstitially in a skin fold between the toes of the right rear extremity of the animal. Five hours after administration, the lymph nodes of the right and left sides of the body were prepared, and a fluorescence image was recorded. The fluorescence of the substances was stimulated by irradiation of the lymph nodes with near-infrared light of wavelength 740 nm, which was produced with an Nd:YAG laser. The fluorescence radiation was detected at a wavelength of >800 nm by an intensified CCD-camera, and the fluorescence images were stored digitally.
- FIG. 6 shows a fluorescence image of lymph nodes five hours after interstitial administration of a formulation with 5 mol % of dye 8 and 95 mol % of 6-[1-O-α-D-mannopyranosyl)-hexanoic acid N-(3-oxa-1H,1H,2H,2H,4H,4H,5H,5H-perfluorotridecyl)-amide. Shown are the mandibular (m, m′), axillary (a, a′), mesenteric (mes), iliac (il, il′), inguinal (in, in′), gluteal (g, g′) and popliteal (p, p′) lymph nodes of the animal. Most lymph nodes of the right (administered) side of the body showed a fluorescence signal, while no lymph nodes of the left side of the body (in each case identified with ′) had a fluorescence signal. The fluorescence-labeled lymph nodes were greenish-colored because of the accumulation of substances.
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The above preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
- In the foregoing and in the above examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
- The entire disclosures of all applications, patents and publications, cited above, and of corresponding German application No. 199 48 650.6-43, filed Sep. 29, 1999, and U.S. Provisional Application Serial No. 60/158,306, filed Oct. 8, 1999, are hereby incorporated by reference.
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
Claims (30)
1. Galenical formulation, characterized in that it contains perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances.
2. Formulation according to claim 1 , wherein the other perfluoroalkyl-containing substances are perfluoroalkyl-containing metal complexes.
3. Formulation according to claim 2 , wherein the formulations contain other perfluoroalkyl-containing substances in addition to the perfluoroalkyl-containing dye molecules and the perfluoroalkyl-containing metal complexes.
4. Formulation according to claim 1 , wherein the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds are present dissolved in a solvent.
5. Formulation according to claim 4 , wherein the solvent is water.
6. Formulation according to claim 4 , wherein the proportion of the perfluoroalkyl-containing dye molecules is between 1 and 10 mol % relative to the total amount of perfluoroalkyl-containing substances.
7. Formulation according to one of claims 1 to 3 , wherein the perfluoroalkyl-containing dye molecules absorb and fluoresce in a spectral range of between 400 and 900 nm.
8. Formulation according to claim 1 , wherein the perfluoroalkyl-containing dye molecules are substances of general formula I:
Rf-L-A (I)
in which Rf represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms, L stands for a linker, and A stands for a dye molecule.
9. Formulation according to claim 8 , whereby linker L represents a direct bond or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COOH, —SO3 groups and/or optionally is interrupted by one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR—, —NRCO—, —SO2—, —NH—, —NR groups or a piperazine, whereby R stands for a C1 to C10 alkyl radical, which optionally is substituted with one or more OH groups and/or is interrupted by one or more oxygen atoms.
10. Formulation according to claim 8 , wherein dye molecule A is a dye from the class of polymethine dyes, xanthine dyes or the heteroaromatic, cationic dyes.
11. Formulation according to claim 8 , wherein dye molecule A is a cyanine dye, squarilium dye, coconium dye, oxonol dye, merocyanine dye, cryptocyanine dye, fluorescein, rhodamine, oxazine, phenoxazine, thiazine or phenothiazine.
12. Formulation according to claim 8 , wherein dye molecule A is a molecule according to Formula II:
in which
D stands for a fragment that corresponds to general formulas III to VI, whereby the position that is characterized with a star means the linkage with B:
and in which B stands for a fragment that corresponds to general formulas VII to XII:
whereby R1 and R2 represent a C1-C4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated, cyclic C5-C6 units or bicyclic C10 units, and whereby the C1-C50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups,
R3 stands for a radical —COOE1, —CONE1E2, —NHCOE1, —NHCONHE1, —NE1E2, —OE1, —OSO3E1, —SO3E1, —SO2NHE1, —E1,
whereby E1 and E2, independently of one another, represent a hydrogen atom, a C1-C4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated cyclic C5-C6 units or bicyclic C10 units, and whereby the C1-C50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups, and/or is substituted with 0 to 5 hydroxy groups,
and whereby R4 stands for a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, or a branched or straight-chain C1-C10 alkyl chain,
b means a number 2 or 3,
and X and Y, independently of one another, mean O, S, —CH═CH— or C(CH3)2.
13. Formulation according to claim 2 , wherein the perfluoroalkyl-containing metal complexes are selected from the following groups of metal complexes:
the gadolinium complex of 10-[1-methyl-2-oxo-3-aza-5-oxo-5-{4-perfluorooctylsulfonyl-piperazin-1-yl}-pentyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane,
the gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-oxa-10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,17-heptadecafluoroheptadecyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane,
1,4,7-tris{1,4,7-tris(N-carboxylatomethyl)-10-(N-1-methyl-3,6-diaza-2,5,8-trioxooctane-1,8-diyl)-1,4,7,10-tetraazacyclododecane, Gd-complex}-10-(N-2H,2H,4H,4H,5H,5H-3-oxa-perfluoro-tridecanoyl)-1,4,7,10-tetraazacyclododecane,
1,4,7-tris{1,4,7-tris[(N-carboxylatomethyl)]-10-[N-1-methyl-3-aza-2,5-dioxopentam-1,5-diyl]-1,4,7,10-tetraazacyclododecane, Gd complex}-10-[2-(N-ethyl-N-perfluorooctylsulfonyl)-amino]-acetyl-1,4,7,10-tetraazacyclododecane,
the gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane,
1,4,7-tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(2,3-dihydroxy-propyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex,
1,4,7-tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex,
1,4,7-tris(carboxylatomethyl)-10-{(3-aza-4-oxo-hexan-5-ylic)-acid-[N-3,6,9,12,15-pentaoxa)-hexadexyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl]-amide}-1,4,7,10-tetraazacyclododecane, gadolinium complex,
and 1,4,7-tris(carboxylatomethyl)-10-[(3-aza-4-oxo-hexan-5-ylic)-acid-N-(5-hydroxy-3-oxa-pentyl)-N-(1H,1H,2H,2H,4H,4H,5H,5H-3-oxa)-perfluorotridecyl)-amide]-1,4,7,10-tetraazacyclododecane, gadolinium complex.
14. Formulation according to claim 3 , wherein the additional perfluoroalkyl-containing substances are compounds of general formula XV:
Rf-L2-G1 (XXXII)
in which Rf represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms, L2 stands for a linker, and G1 stands for a hydrophilic group.
15. Formulation according to claim 14 , wherein linker L2 is a direct bond, an —SO2 group or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COO—, —SO3 groups and/or optionally contains one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR—, —NRCO—, —SO2—, —PO4, —NH—, —NR groups, an aryl ring or a piperazine, whereby R stands for a C1 to C20 alkyl radical, which in turn can contain one or more O-atoms and/or can be substituted with —COO− or SO3 groups.
16. Formulation according to claim 14 , wherein hydrophilic group G1 stands for a monosaccharide or disaccharide, one or more adjacent —COO− or —SO3 groups, a dicarboxylic acid, an isophthalic acid, a picolinic acid, a benzenesulfonic acid, a tetrahydropyrandicarboxylic acid, a 2,6-pyridinedicarboxylic acid, a quaternary ammonium ion, an aminopolycarboxylic acid, an aminodipolyethyleneglycolsulfonic acid, an aminopolyethylene glycol group, an SO2—(CH2)2—OH group, a polyhydroxyalkyl chain with at least two hydroxyl groups or one or more polyethylene glycol chains with at least two glycol units, whereby the polyethylene glycol chains are terminated by an —OH or —OCH3 group.
17. Formulation according to claim 1 , wherein the perfluoroalkyl chains of the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds contain 6 to 12 carbon atoms.
18. Formulation according to claim 17 , wherein the perfluoroalkyl chains contain 8 carbon atoms in each case.
19. Substances of general formula I
Rf-L-A (I)
in which Rf represents a straight-chain or branched perfluoroalkyl radical with 4 to 30 carbon atoms, L stands for a linker and A stands for a dye molecule from the class of polymethine dyes, xanthine dyes or the heteroaromatic, cationic dyes.
20. Substances according to claim 19 , wherein linker L represents a direct bond or a straight-chain or branched carbon chain with up to 20 carbon atoms, which can be substituted with one or more —OH, —COOH, —SO3 groups and/or optionally is interrupted by one or more —O—, —S—, —CO—, —CONH—, —NHCO—, —CONR—, —NRCO—, —SO2—, —NH—, —NR groups or a piperazine, whereby R stands for a C1 to C10 alkyl radical, which optionally is substituted with one or more OH groups.
21. Substances according to claim 19 , wherein dye molecule A is a cyanine dye, squarilium dye, croconium dye, oxonol dye, merocyanine dye, cryptocyanine dye, fluorescein dye, rhodamine dye, oxazine dye, phenoxazine dye, thiazine dye or phenothiazine dye.
22. Substances according to claim 22 , wherein dye molecule A is a molecule according to formula II:
in which
D stands for a fragment that corresponds to general formulas III to VI, whereby the position that is characterized with a star means the linkage with B:
and in which B stands for a fragment that corresponds to general formulas VII to XII:
whereby R1 and R2 represent a C1 -C4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated, cyclic C5-C6 units or bicyclic C10 units, and whereby the C1-C50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups,
R3 stands for a radical —COOE1, —CONE1E2, —NHCOE1, —NHCONHE1, —NE1E2, —OE1, —OSO3E1, —SO3E1, —SO2NHE1, —E1,
whereby E1 and E2, independently of one another, represent a hydrogen atom, a C1-C4 sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50 alkyl chain, whereby the chain or parts of this chain optionally can form one or more aromatic or saturated cyclic C5-C6 units or bicyclic C10 units, and whereby the C1-C50 alkyl chain optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups, and/or is substituted with 0 to 5 hydroxy groups,
and whereby R4 stands for a hydrogen atom, a fluorine, chlorine, bromine or iodine atom, or a branched or straight-chain C1-C10 alkyl chain,
b means a number 2 or 3,
and X and Y, independently of one another, mean O, S, —CH═CH— or C(CH3)2.
23. Process for the production of galenical formulations according to claim 1 , wherein the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds are dissolved in a solvent while being stirred vigorously.
24. Process for the production of galenical formulations according to claim 1 , wherein the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds are dissolved in a solvent while being treated simultaneously with ultrasound.
25. Process for the production of galenical formulations according to claim 1 , wherein the perfluoroalkyl-containing dye molecules and the other perfluoroalkyl-containing compounds are dissolved in a solvent while being treated simultaneously with microwaves.
26. Process for the production of galenical formulations according to claim 1 , wherein the perfluoroalkyl-containing dye molecules are dissolved in a solvent, the other perfluoroalkyl-containing compounds are dissolved in another solvent, the two solutions are combined, and one of the two solvents is distilled off.
27. Solid formulation according to claim 1 , wherein it is produced by freeze-drying a solution, which contains perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances.
28. Use of galenical formulations according to claim 1 for the production of contrast media for optical diagnosis, fluorescence diagnosis, near-infrared diagnosis, nuclear spin tomography, imaging with use of x-rays (x-ray or computer tomography) and for ultrasound imaging.
29. Use of galenical formulations according to claim 1 for the production of contrast media for visualizing lymph nodes or blood pools.
30. Use of galenical formulations according to claim 1 for the production of agents for intraoperative diagnosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/193,187 US20030095924A1 (en) | 1999-09-29 | 2002-07-12 | Galenical formulations |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1999148650 DE19948650A1 (en) | 1999-09-29 | 1999-09-29 | Contrast agent formulations containing perfluoroalkylated dye and other perfluoroalkylated compound, having high organ specificity, especially for lymph nodes, useful e.g. in fluorescence or near infrared diagnosis |
DE19948650.6-43 | 1999-09-29 | ||
US15830699P | 1999-10-08 | 1999-10-08 | |
US09/672,051 US6447749B1 (en) | 1999-09-29 | 2000-09-29 | Perfluoro-alkyl containing dye molecules and galencial formulations |
US10/193,187 US20030095924A1 (en) | 1999-09-29 | 2002-07-12 | Galenical formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/672,051 Division US6447749B1 (en) | 1999-09-29 | 2000-09-29 | Perfluoro-alkyl containing dye molecules and galencial formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030095924A1 true US20030095924A1 (en) | 2003-05-22 |
Family
ID=26055233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/672,051 Expired - Fee Related US6447749B1 (en) | 1999-09-29 | 2000-09-29 | Perfluoro-alkyl containing dye molecules and galencial formulations |
US10/193,187 Abandoned US20030095924A1 (en) | 1999-09-29 | 2002-07-12 | Galenical formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/672,051 Expired - Fee Related US6447749B1 (en) | 1999-09-29 | 2000-09-29 | Perfluoro-alkyl containing dye molecules and galencial formulations |
Country Status (2)
Country | Link |
---|---|
US (2) | US6447749B1 (en) |
EP (1) | EP1088559A3 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4445065A1 (en) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Methods for in-vivo diagnostics using NIR radiation |
DE19603033A1 (en) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics |
EP1088559A3 (en) * | 1999-09-29 | 2002-10-02 | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN | Galenic formulations |
DE19948651B4 (en) * | 1999-09-29 | 2006-10-05 | Schering Ag | Galenic formulations containing para and diamagnetic perfluorinated compounds, their preparation and use |
US7181266B2 (en) * | 2003-03-04 | 2007-02-20 | Massachusetts Institute Of Technology | Materials and methods for near-infrared and infrared lymph node mapping |
US20050020922A1 (en) * | 2003-03-04 | 2005-01-27 | Frangioni John V. | Materials and methods for near-infrared and infrared intravascular imaging |
ES2279422T3 (en) * | 2003-08-18 | 2007-08-16 | Novartis Ag | SUITABLE 3H-PHENOXAZINE DERIVATIVES AS IMAGE TRAINING AGENTS IN THE NEXT INFRARED REGION, PREPARATION AND USE OF THE SAME. |
US7125945B2 (en) * | 2003-09-19 | 2006-10-24 | Varian, Inc. | Functionalized polymer for oligonucleotide purification |
US9388206B2 (en) | 2011-05-06 | 2016-07-12 | Basf Se | Chromophores with perfluoroalkyl substituents |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
US10975060B2 (en) | 2016-11-28 | 2021-04-13 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
PE20211471A1 (en) | 2018-11-23 | 2021-08-05 | Bayer Ag | FORMULATION OF CONTRAST MEANS AND PROCESS TO PREPARE THEM |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3973969A (en) * | 1972-06-21 | 1976-08-10 | Fuji Photo Film Co., Ltd. | Silver halide photographic emulsion |
US4853310A (en) * | 1987-05-22 | 1989-08-01 | Minnesota Mining And Manufacturing Company | Triiolide salts of cyanine dyes suitable for sensitization of photoconductive systems |
US5254455A (en) * | 1991-12-02 | 1993-10-19 | Polaroid Corporation | Silver halide emulsions spectrally sensitized to infrared radiation with novel cyanine dyes |
US5277895A (en) * | 1990-11-08 | 1994-01-11 | Schering Aktiengesellschaft | Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives, process for their production and pharmaceutical agents containing these derivatives |
US5281593A (en) * | 1990-07-31 | 1994-01-25 | Lilly Industries Limited | Certain indole derivatives useful as leukotriene antagonists |
US5460800A (en) * | 1993-03-16 | 1995-10-24 | Alliance Pharmaceutical Corp. | Labeled fluorocarbon compositions |
US5637448A (en) * | 1994-06-17 | 1997-06-10 | Konica Corporation | Silver halide light-sensitive photographic material |
US5690909A (en) * | 1993-05-24 | 1997-11-25 | Schering Aktiengesellschaft | Fluorine-containing macrocyclic metal complexes |
US5851752A (en) * | 1994-07-11 | 1998-12-22 | Fuji Photo Film Co., Ltd. | Silver halide photographic material comprising hole-injection-type sensitizing dye(s) and supersensitizing compound(s) |
US5980864A (en) * | 1990-03-19 | 1999-11-09 | Schering Aktiengellsellschaft | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
US5986086A (en) * | 1997-06-20 | 1999-11-16 | Amersham Pharmacia Biotech Inc. | Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides |
US6214533B1 (en) * | 1998-04-10 | 2001-04-10 | Konica Corporation | Thermally developable photosensitive material |
US6447749B1 (en) * | 1999-09-29 | 2002-09-10 | Schering Aktiengesellschaft | Perfluoro-alkyl containing dye molecules and galencial formulations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB686678A (en) * | 1949-07-10 | 1953-01-28 | Minnesota Mining & Mfg | Improvements in or relating to process of preparing derivatives of fluorocarbon acid, fluoride compounds and the derivatives resulting from said process |
BE787340A (en) * | 1971-08-12 | 1973-02-09 | Agfa Gevaert Nv | SENSITIVE, THERMICALLY DEVELOPABLE MATERIAL BASED ON SPECTRALLY SENSITIZED ORGANIC SILVER SALTS |
EP0636493B1 (en) * | 1993-07-30 | 1997-03-26 | Eastman Kodak Company | Infrared-absorbing cyanine dyes for laser ablative imaging |
DE19603033A1 (en) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics |
WO1998048845A1 (en) * | 1997-04-29 | 1998-11-05 | Nycomed Imaging As | Method of demarcating tissue |
DE19729013A1 (en) * | 1997-07-03 | 1999-02-04 | Schering Ag | Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics |
DE19731591C2 (en) * | 1997-07-17 | 1999-09-16 | Schering Ag | Pharmaceutical compositions containing triiodoaromatics containing perfluoroalkyl groups and their use in tumor therapy and interventional radiology |
EP1120119A4 (en) * | 1998-09-17 | 2003-10-01 | Nippon Kayaku Kk | Remedies for photochemotherapy |
DE19948651B4 (en) * | 1999-09-29 | 2006-10-05 | Schering Ag | Galenic formulations containing para and diamagnetic perfluorinated compounds, their preparation and use |
-
2000
- 2000-09-28 EP EP00250324A patent/EP1088559A3/en not_active Withdrawn
- 2000-09-29 US US09/672,051 patent/US6447749B1/en not_active Expired - Fee Related
-
2002
- 2002-07-12 US US10/193,187 patent/US20030095924A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3973969A (en) * | 1972-06-21 | 1976-08-10 | Fuji Photo Film Co., Ltd. | Silver halide photographic emulsion |
US4853310A (en) * | 1987-05-22 | 1989-08-01 | Minnesota Mining And Manufacturing Company | Triiolide salts of cyanine dyes suitable for sensitization of photoconductive systems |
US5980864A (en) * | 1990-03-19 | 1999-11-09 | Schering Aktiengellsellschaft | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
US5281593A (en) * | 1990-07-31 | 1994-01-25 | Lilly Industries Limited | Certain indole derivatives useful as leukotriene antagonists |
US5277895A (en) * | 1990-11-08 | 1994-01-11 | Schering Aktiengesellschaft | Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives, process for their production and pharmaceutical agents containing these derivatives |
US5254455A (en) * | 1991-12-02 | 1993-10-19 | Polaroid Corporation | Silver halide emulsions spectrally sensitized to infrared radiation with novel cyanine dyes |
US5460800A (en) * | 1993-03-16 | 1995-10-24 | Alliance Pharmaceutical Corp. | Labeled fluorocarbon compositions |
US5690909A (en) * | 1993-05-24 | 1997-11-25 | Schering Aktiengesellschaft | Fluorine-containing macrocyclic metal complexes |
US5637448A (en) * | 1994-06-17 | 1997-06-10 | Konica Corporation | Silver halide light-sensitive photographic material |
US5851752A (en) * | 1994-07-11 | 1998-12-22 | Fuji Photo Film Co., Ltd. | Silver halide photographic material comprising hole-injection-type sensitizing dye(s) and supersensitizing compound(s) |
US5986086A (en) * | 1997-06-20 | 1999-11-16 | Amersham Pharmacia Biotech Inc. | Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides |
US6214533B1 (en) * | 1998-04-10 | 2001-04-10 | Konica Corporation | Thermally developable photosensitive material |
US6447749B1 (en) * | 1999-09-29 | 2002-09-10 | Schering Aktiengesellschaft | Perfluoro-alkyl containing dye molecules and galencial formulations |
Also Published As
Publication number | Publication date |
---|---|
US6447749B1 (en) | 2002-09-10 |
EP1088559A2 (en) | 2001-04-04 |
EP1088559A3 (en) | 2002-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100340290B1 (en) | In-vivo diagnostic process by near infrared radiation | |
Licha et al. | Hydrophilic Cyanine Dyes as Contrast Agents for Near‐infrared Tumor Imaging: Synthesis, Photophysical Properties and Spectroscopic In vivo Characterization¶ | |
DE60133626T2 (en) | HYDROPHILIC CYANINE DYES | |
US6447749B1 (en) | Perfluoro-alkyl containing dye molecules and galencial formulations | |
US20040223913A1 (en) | Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients | |
Licha et al. | Synthesis and characterization of cyanine dyes as contrast agents for near-infrared imaging | |
AU779026B2 (en) | Antibody dye conjugates for binding to target structures of angiogenesis in order to intraoperatively depict tumor peripheries | |
DE19948650A1 (en) | Contrast agent formulations containing perfluoroalkylated dye and other perfluoroalkylated compound, having high organ specificity, especially for lymph nodes, useful e.g. in fluorescence or near infrared diagnosis | |
PL203535B1 (en) | Antibody-dye conjugates, pharmaceuticals containing them and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |